US20040076625A1 - Enhanced vaccines - Google Patents

Enhanced vaccines Download PDF

Info

Publication number
US20040076625A1
US20040076625A1 US10/673,594 US67359403A US2004076625A1 US 20040076625 A1 US20040076625 A1 US 20040076625A1 US 67359403 A US67359403 A US 67359403A US 2004076625 A1 US2004076625 A1 US 2004076625A1
Authority
US
United States
Prior art keywords
polypeptide
thr
ser
ige
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/673,594
Inventor
Lars Hellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resistentia Pharmaceuticals AB
Original Assignee
Resistentia Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals AB filed Critical Resistentia Pharmaceuticals AB
Priority to US10/673,594 priority Critical patent/US20040076625A1/en
Publication of US20040076625A1 publication Critical patent/US20040076625A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention relates to methods and materials involved in the treatment of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal.
  • Mammals are susceptible to many diseases and illnesses including bacterial infections, viral infections, and IgE-related diseases such as allergies.
  • infections are characterized by the invasion and multiplication of microorganisms (e.g., bacteria, fungi, and viruses) within body tissues.
  • microorganisms e.g., bacteria, fungi, and viruses
  • the polio vaccine can prevent poliovirus infections.
  • a vaccine is a suspension of attenuated or killed microorganisms.
  • IgE-related diseases are mediated by a class of immunoglobulin designated as immunoglobulin E (IgE).
  • IgE antibodies are a major cause of hypersensitivity reactions found within the human population despite their normally very low concentration in human plasma (10-400 ng/mL). The effects are due to the interaction of IgE antibodies with the high-affinity receptor for IgE on mast cells and basophilic leukocytes.
  • Cross-linking of two IgE receptors on the surface of these cell types initiates the release of a number of physiologically active substances such as histamine, PAF (platelet activating factor), heparin, leukotrienes, prostaglandins, thromboxanes, and chemotactic factors for eosinophilic and neutrophilic granulocytes.
  • physiologically active substances such as histamine, PAF (platelet activating factor), heparin, leukotrienes, prostaglandins, thromboxanes, and chemotactic factors for eosinophilic and neutrophilic granulocytes.
  • these mediators cause the direct symptoms of IgE-mediated allergic reactions (type I hypersensitivity).
  • Disease conditions belonging to this-group can include asthma, fur allergies, pollen allergies, food allergies, and eczema.
  • the high-affinity receptor for IgE has been characterized. This receptor appears to be present on mast cells, basophilic leucocytes, eosinophils, monocytes, and Langerhan cells. In addition, the receptor is a complex of three different subunits ( ⁇ , ⁇ , and ⁇ chains). The ⁇ chain is localized mainly extra-cellularly and appears to interact with the IgE molecule. Previous studies of the epsilon chain of the IgE molecule have suggested that a region of 76 amino acids at the border between the CH2 and CH3 domains (CH refers to the constant domains in the heavy chain) is important for the interaction between the IgE molecule and its high-affinity receptor.
  • CH refers to the constant domains in the heavy chain
  • a peptide corresponding to this region was shown to inhibit the interaction between native IgE and its high-affinity receptor in vitro at a molar ratio of nearly 1:1 compared to the whole CH2-CH3-CH4 region (Helm et al., Nature 331, 180-183 (1988)).
  • This peptide was also shown to inhibit an IgE-mediated flare reaction in allergen stimulation. In this case, however, the concentration was about 10 times the concentration needed to exhibit the same inhibitory effect with native IgE (Helm et al., Proc. Natl. Acad Sci. USA 86, 9465-9469 (1989)).
  • the invention relates to methods and materials involved in the treatment and prevention of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal. Such methods and materials can be used to treat atopic allergies in mammals such as humans, dogs, and pigs.
  • a vaccine conjugate can be designed to contain at least two polypeptides with each polypeptide having at least two similar amino acid segments such that the administration of the conjugate to a mammal can induce an immune response against at least a portion of one of the polypeptides.
  • Such immune responses can be more potent than the responses induced by any of the polypeptides in an unconjugated form or any conjugate of polypeptides lacking at least two similar amino acid segments.
  • the vaccine conjugates described herein can be used to provide mammals with substantial protection against a wide range of either self (e.g., IgE molecules) or non-self (e.g., viral polypeptides) antigens.
  • a vaccine conjugate can be designed to contain a polypeptide having a cytokine activity such that a potent immune response is induced against another polypeptide within the conjugate.
  • Such immune responses can be more potent than the responses induced by a conjugate lacking a polypeptide having a cytokine activity.
  • a conjugate containing a polypeptide having a cytokine activity as well as an immunogenic polypeptide presumably concentrates cytokine activity to the localized area containing the immunogenic polypeptide.
  • the polypeptide having cytokine activity can stimulate cells that participate in generating a specific immune response against the immunogenic polypeptide.
  • the invention is based on the discovery that polypeptides containing a self IgE portion and a non-self IgE portion are immunogenic and induce an effective anti-self IgE response in mammals.
  • immunogenic polypeptides can be used as a vaccine to induce an anti-self IgE response that counteracts the hypersensitivity induced by self IgE antibodies.
  • the immunogenic polypeptides described herein induce the production of anti-self IgE antibodies that presumably have specificity for the portion of the IgE molecule that interacts with the high-affinity IgE receptor.
  • the anti-self IgE antibodies can interact with the self-IgE antibodies such that the self IgE antibodies are unable to bind to the high-affinity IgE receptor. This inhibition of receptor binding presumably reduces the hypersensitivity induced by self IgE antibodies. Thus, the degree of IgE-induced effects can be reduced as more anti-self IgE antibodies are produced.
  • the invention features an immunogenic polypeptide having a self IgE portion and a non-self IgE portion.
  • the immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal (e.g., human).
  • the self portion can contain at least a portion of a CH3 domain of IgE.
  • the polypeptide can be capable of dimerizing to form a soluble immunogenic dimer effective to induce the anti-self IgE response in the mammal.
  • the non-self IgE portion can contain a first region and a second region with the self IgE portion being located between the first and second regions of the non-self IgE portion.
  • the first region can contain at least a portion of an IgE CH2 domain
  • the second region can contain at least a portion of an IgE CH4 domain.
  • the non-self IgE portion can contain an IgE sequence present in a non-placental mammal (e.g., opossum, platypus, koala, kangaroo, wallaby, and wombat).
  • the self IgE portion can lack the CH2 domain of an IgE antibody.
  • the immunogenic polypeptide can contain a eukaryotic post-translational modification.
  • the immunogenic polypeptide can contain a polyhistidine sequence.
  • the anti-self IgE response can be a polyclonal response.
  • the invention features a nucleic acid molecule containing a nucleic acid sequence that encodes an immunogenic polypeptide.
  • the immunogenic polypeptide contains a self IgE portion as well as a non-self IgE portion, and is effective to induce an anti-self IgE response in a mammal.
  • the nucleic acid molecule can contain an additional nucleic acid sequence that encodes an amino. acid sequence that promotes the secretion of the immunogenic polypeptide from a eukaryotic cell.
  • Another embodiment of the invention features a host cell (e.g., eukaryotic cell) containing a nucleic acid molecule that has a nucleic acid sequence that encodes an immunogenic polypeptide.
  • the immunogenic polypeptide contains a self IgE portion as well as a non-self IgE portion, and is effective to induce an anti-self IgE response in a mammal.
  • Another embodiment of the invention features a soluble immunogenic dimer containing two immunogenic polypeptides that are capable of dimerizing to form the soluble immunogenic dimer.
  • Each of the two immunogenic polypeptides contains a self IgE portion and a non-self IgE portion, and the soluble immunogenic dimer is effective to induce an anti-self IgE response in a mammal.
  • Another embodiment of the invention features a vaccine containing an immunogenic polypeptide having a self IgE portion and a non-self IgE portion.
  • the immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal.
  • the vaccine can contain a pharmaceutically acceptable carrier.
  • Another embodiment of the invention features a method for making a nucleic acid molecule that encodes an immunogenic polypeptide effective to induce an anti-self IgE response in a mammal.
  • the method includes combining first and second nucleic acid sequences to form the nucleic acid molecule, where the first nucleic acid sequence encodes at least a portion of an IgE molecule present within the mammal, and where the second nucleic acid sequence encodes at least a portion of an IgE molecule not present in the mammal.
  • Another embodiment of the invention features a method for making a nucleic acid molecule that encodes an immunogenic polypeptide effective to induce an anti-self IgE response in a mammal.
  • the method includes (a) selecting a first nucleic acid sequence, where the first nucleic acid sequence encodes at least a portion of an IgE molecule present within the mammal, (b) selecting a second nucleic acid sequence, where the second nucleic acid sequence encodes at least a portion of an IgE molecule not present in the mammal, and (c) combining the first and second nucleic acid sequences to form the nucleic acid molecule.
  • the invention features a vaccine complex for vaccinating a mammal (e.g., human).
  • the complex contains a first and second polypeptide.
  • Each of the first and second polypeptides contains at least two similar amino acid sequences at least five amino acid residues in length.
  • the first and second polypeptides are connected to form the complex, and administration of the complex to the mammal induces an immune response against at least a portion of the first or second polypeptide.
  • the first and/or second polypeptide can contains an amino acid sequence expressed by the mammal.
  • the first and second polypeptides can be identical, and can form a dimer.
  • the connection of the first and second polypeptides can include a disulfide bond.
  • the connection of the first and second polypeptides can include a non-covalent interaction.
  • the first and/or second polypeptide can contain a linker site (e.g., a polyhistidine sequence).
  • the amino and carboxyl termini of the first and/or second polypeptide can contain the linker site.
  • the complex can include a linking molecule (e.g., an antibody such as an anti-polyhistidine antibody).
  • a linking molecule can connects the first and second polypeptide.
  • the complex can contain a third polypeptide, where the third polypeptide has a cytokine activity.
  • the cytokine activity can be an activity of a cytokine such as interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , TNF- ⁇ , IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, and granulocyte-macrophage colony stimulating factor.
  • a linking molecule can connect the third polypeptide to the first or second polypeptide.
  • the similar amino acid sequences can be greater than about twenty amino acid residues in length.
  • the complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody).
  • the invention features a vaccine complex for vaccinating a mammal (e.g., human).
  • the complex contains a first polypeptide connected to a second polypeptide, where the first polypeptide contains at least two similar amino acid sequences at least five amino acids in length.
  • the second polypeptide has a cytokine activity, and administration of the complex to the mammal induces an immune response against at least a portion of the first polypeptide.
  • the first polypeptide can contain an amino acid sequence expressed by the mammal.
  • the connection of the first and second polypeptides can include a non-covalent interaction.
  • the first and/or second polypeptide can contain a linker site (e.g., a polyhistidine sequence).
  • the amino and carboxyl termini of the first polypeptide can contain a linker site.
  • the complex can contain a linking molecule (e.g., an antibody such as an anti-polyhistidine antibody).
  • the cytokine activity can be an activity of a cytokine such as interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , TNF- ⁇ , IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, and granulocyte-macrophage colony stimulating factor.
  • the complex can contain a third polypeptide.
  • the first and third polypeptides can be identical and can form a dimer.
  • the connection of the first and third polypeptides can include a disulfide bond.
  • the similar amino acid sequences can be greater than about twenty amino acid residues in length.
  • the complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody).
  • Another embodiment of the invention features a vaccine complex for vaccinating a mammal (e.g., human).
  • the complex contains a first, second, and third polypeptide, where the first, second, and third polypeptides are connected to form the complex.
  • the first polypeptide has a first cytokine activity.
  • the second polypeptide has a second cytokine activity.
  • the administration of the complex to the mammal induces an immune response against at least a portion of the third polypeptide.
  • the third polypeptide can contain an amino acid sequence expressed by the mammal.
  • the connections of the first, second, and third polypeptides can include non-covalent interactions.
  • the first, second, and/or third polypeptide can contain a linker site.
  • the complex can contain a linking molecule.
  • the third polypeptide can contain at least two similar amino acid sequences at least five amino acids in length.
  • the complex can contain an Fc-gamma receptor II blocking molecule (e.g.
  • Another embodiment of the invention features a vaccine complex for vaccinating a mammal (e.g., human).
  • the complex contains a first polypeptide connected to a second polypeptide, where the first polypeptide is a polypeptide having interferon- ⁇ or interferon- ⁇ activity, and administration of the complex to the mammal induces an immune response against at least a portion of the second polypeptide.
  • the second polypeptide can contain an amino acid sequence expressed by the mammal.
  • the connection of the first and second polypeptides can include a non-covalent interaction.
  • the first and/or second polypeptide can contain a linker site.
  • the complex can contain a linking molecule.
  • the second polypeptide can contain at least two similar amino acid sequences at least five amino acids in length.
  • the complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody).
  • Another aspect of the invention features a vaccine for vaccinating a mammal (e.g., human).
  • the vaccine contains an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody) and a polypeptide, where administration of the vaccine to the mammal induces an immune response against at least a portion of the polypeptide.
  • the polypeptide can contain an amino acid sequence expressed by the mammal.
  • the Fc-gamma receptor II blocking molecule and polypeptide can be connected, and the connection can include a non-covalent interaction.
  • FIG. 1 is a diagram comparing the amino acid sequences of the CH2-CH3-CH4 domains of human, rat, and opossum IgE, in the upper, middle, and lower rows, respectively.
  • the opossum sequence also contains an N-terminal signal sequence followed by six histidine residues.
  • FIGS. 2 A-B contain diagrams comparing the amino acid sequences of various polypeptides containing the following components: opossum CH2—rat CH3—opossum CH4 (ORO); opossum-CH2—rat N-term CH3—opossum C-term CH3—opossum CH4 (ORO-trunc); opossum CH2—mouse CH3—opossum CH4 (OMO); opossum CH2—CH3—CH4 (OOO); platypus CH2—CH3—CH4 (PPP); opossum CH2—human CH3—opossum CH4 (OHO); opossum CH2—pig CH3—opossum CH4 (OPO); and opossum CH2—dog CH3—opossum CH4 (ODO).
  • the arrows indicate domain borders.
  • FIGS. 3 A-C contain diagrams depicting the analysis of immune responses against an ORO immunogenic polypeptide in a panel of three different strains of rats.
  • the level of rat IgG anti-IgE antibodies directed against native rat IgE was measured by an ELISA.
  • Native rat IgE was used at a concentration of 5 ⁇ g/mL for coating of ELISA plates.
  • Successive 1/5 dilutions of serum from each of the individual rats were tested by color reaction in the ELISA.
  • Six vaccinated rats were analyzed together with four control rats from each strain.
  • FIG. 4 is a diagram depicting an analysis of the immune responses against an ORO immunogenic polypeptide as well as OOO and PPP control polypeptides.
  • the invention provides methods and materials for the treatment of various diseases such as infections and IgE-related diseases. Specifically, the invention provides methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal.
  • the invention provides vaccine conjugates that contain at least two polypeptides with each of those polypeptides having at least two similar amino acid segments.
  • conjugate refers to any composition containing at least two polypeptides that are directly or indirectly connected via one or more covalent or non-covalent bonds.
  • a conjugate can contain ten sequentially connected polypeptides (e.g., number one is connected to number two, number two is connected to number three, number three is connected to number four, etc.).
  • polypeptides refers to any type of covalent or non-covalent bond including, without limitation, single bonds, double bonds, triple bonds, disulfide bonds, hydrogen bonds, hydrophobic interactions, van der Waals interactions, and any combination thereof.
  • a disulfide bond can connect polypeptide number one to polypeptide number two.
  • an antibody can connect polypeptide numbers one and two.
  • polypeptides one and two each would contain an epitope recognized by the antibody such that the resulting conjugate contains polypeptide number one non-covalently connected to the antibody which is non-covalently connected to polypeptide number two.
  • polypeptide numbers one and two in this example can have an identical amino acid sequence.
  • amino acid segment refers to a contiguous stretch of amino acid sequence within a polypeptide.
  • amino acid sequence from residues 30 to 40 within a 100 amino acid polypeptide would be considered an amino acid segment.
  • an amino acid segment can be any length greater than about five amino acid residues (e.g., greater than about six, seven, eight, nine, ten, 15, 20, 25, 30, 40, 50, 75, 100, 150, or 200 amino acid residues).
  • an amino acid segment can be the entire CH3 domain of an IgE antibody.
  • similar as used herein with respect to at least two amino acid segments means the segments are at least about 50 percent identical in amino acid sequence.
  • similar amino acid segments can be about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100 percent identical.
  • percent amino acid sequence identity between one amino acid segment and another is calculated as follows. First, the amino acid sequences of the two amino acid segments are aligned using the MEGALIGN® (DNASTAR, Madison, Wis., 1997) sequence alignment software following the Jotun Heim algorithm with the default settings. Second, the number of matched positions between the two aligned amino acid sequences is determined.
  • a matched position refers to a position in which identical residues occur at the same position as aligned by the MEGALIGN® sequence alignment software. Third, the number of matched positions is divided by the total number of positions, and the resulting value multiplied by 100 to obtain the percent identity.
  • a vaccine conjugate of the invention contains at least two polypeptides with each of those polypeptides having at least two similar amino acid segments.
  • a vaccine conjugate can contain two, three, four, five, six, seven, eight, nine, ten, 15, 20, 25, or 30 polypeptides with each having at least two similar amino acid segments.
  • a polypeptide containing at least two similar amino acid segments can contain two, three, four, five, six, seven, eight, nine, ten, or more similar amino acid segments.
  • a vaccine conjugate of the invention can contain any number of polypeptides not having at least two similar amino acid segments.
  • a vaccine conjugate can contain four polypeptides each having a 30 amino acid residue segment repeated three times as well as two polypeptides each lacking similar amino acid segments.
  • a vaccine conjugate contains a polypeptide that will act as an antigen against which an immune response is desired.
  • a vaccine conjugate within the scope of the invention can contain any type of polypeptide including, without limitation, bacterial polypeptides, fungal polypeptides, viral polypeptides, and mammalian polypeptides.
  • a vaccine conjugate can contain five hepatitis C virus polypeptides. It is noted that each polypeptide of a conjugate can have an identical amino acid sequence.
  • a polypeptide of a vaccine conjugate typically contains similar amino acid segments each of which can act as a defined antigenic unit against which an immune response is desired.
  • a polypeptide of a vaccine conjugate can contain similar amino acid segments that correspond to any region from a polypeptide including, without limitation, receptor binding regions, ligand binding regions, enzyme active sites, enzyme cleavage sites of polypeptide substrates, antigen-binding regions of antibodies, and epitopes recognized by antibodies.
  • a polypeptide of a vaccine conjugate can contain three similar amino acid segments that each correspond to the enzyme active site of enzyme X. It is noted that similar amino acid segments can be in tandem or dispersed throughout a polypeptide.
  • the administration of a vaccine conjugate results in the formation of antibodies having specificity for an epitope formed by at least a portion of the similar amino acid segments within one of the polypeptides of the vaccine conjugate.
  • any method can be used to make the polypeptides of a vaccine conjugate including, without limitation, prokaryotic expression systems, eukaryotic expression systems, and chemical synthesis techniques.
  • a polypeptide of a vaccine conjugate can be obtained from natural tissue sources.
  • a brain glycopolypeptide can be obtained from brain tissue.
  • each different polypeptide of a conjugate is made independently, or isolated independently, and then used to form a conjugate.
  • polypeptides can be purified prior to being used to form a conjugate. Any method can be used to purify polypeptides including, without limitation, fractionation, centrifugation, and chromatography.
  • polypeptides containing a polyhistidine sequence can be purified using affinity chromatography. Once obtained, the polypeptides can be connected using any method.
  • a polypeptide sample can be incubated with a linking molecule such that individual polypeptides form conjugates.
  • a linking molecule is any molecule that connects two polypeptides.
  • a linking molecule is a molecule with two reactive groups or sites that are capable of interacting with and thereby forming a link between amino acid residues from two polypeptides.
  • a linking molecule can be a specific linking molecule such as an antibody or a non-specific linking molecule such as a chemical reagent (e.g., glutaraldehyde and formaldehyde).
  • any antibody can be used as a linking molecule.
  • an anti-polyhistidine antibody or an anti-epitope tag antibody such as an anti-FLAG® epitope antibody or anti-hemagglutinin (HA) tag antibody can be used to connect two polypeptides.
  • FLAG® epitopes are described in U.S. Pat. Nos. 4,703,004 and 4,782,137. It is noted that the polypeptides to be connected with a specific linking molecule need to contain the specific site recognized by the linking molecule. For example, to connect two polypeptides with an anti-polyhistidine antibody, each polypeptide must contain the polyhistidine epitope recognized by that antibody.
  • the specific site recognized by a specific linking molecule such as an antibody is referred to as a linker site.
  • Any method can be used to make a polypeptide that contains a linker site such that a particular antibody can be used as a linking molecule.
  • common molecular cloning techniques can be used to introduce the nucleic acid that encodes a FLAG tag epitope into the nucleic acid that encodes a particular polypeptide.
  • a linker site can be located at any position.
  • a polyhistidine sequence can be at the N-terminus, C-terminus, or an internal position of a polypeptide.
  • a polypeptide can contain more than one linker site.
  • a polypeptide can have a polyhistidine sequence at an internal position as well as at the C-terminus. Further, a polypeptide can contain different linker sites. For example, a polypeptide can have a polyhistidine sequence at an internal position and a FLAG tag epitope at the C-terminus.
  • two or more polypeptides can be made such that they are connected via a covalent bond.
  • two polypeptides can be made as a fusion protein such that they are connected by a peptide bond.
  • a polypeptide can be made in a cell line that promotes the formation of disulfide bonds between, for example, two identical polypeptides. In this case, the conjugate would be a homodimer.
  • any polypeptide can be engineered to contain one or more cysteine residues such that the polypeptides form conjugates via cysteine bridges.
  • a polypeptide can be made to contain N- and C-terminal cysteine residues such that conjugates of varying size are formed intracellularly.
  • biotin and avidin can be used to form conjugates.
  • polypeptides can be designed, or chemically treated, to contain biotin molecules at the C- and N-terminal ends. These biotin-containing polypeptide can be incubated with avidin molecules that are capable of simultaneously interacting with two or more biotin molecules. In this case, a single avidin molecule can link two biotin-containing polypeptides to form a conjugate.
  • chelating molecules that can simultaneously bind two or more ions (e.g., Ni ++ , Cu ++ , Co ++ , and Zn ++ ) can be used to form conjugates.
  • a copper chelating molecule that can interact with two copper ions can be used to link two polypeptides containing a polyhistidine sequence.
  • a single copper ion can interact with each polyhistidine sequence while a single copper chelating molecule links the two polypeptides to form a conjugate.
  • immunostimulating complexes can be used to form conjugates.
  • an iscom can be designed to contain copper ions such that polypeptides containing a polyhistidine sequence can be conjugated.
  • a nucleic acid molecule is constructed such that a particular polypeptide is expressed.
  • a nucleic acid molecule can be constructed to encode a polypeptide having three similar amino acid segments as well as a polyhistidine sequence at its C-terminus.
  • the nucleic acid molecule can be introduced into a host cell such that the polypeptide is produced. Any host cell can be used including, without limitation, prokaryotic cells (e.g., bacteria) and eukaryotic cells (e.g., human cells). Once produced, the polypeptide can be purified and used to make the desired vaccine conjugate.
  • nucleic acid encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA.
  • the nucleic acid can be double-stranded or single-stranded. Where single-stranded, the nucleic acid can be the sense strand or the antisense strand. In addition, nucleic acid can be circular or linear.
  • Nucleic acid can be obtained using common molecular cloning or chemical nucleic acid synthesis procedures and techniques, including PCR.
  • PCR refers to a procedure or technique in which target nucleic acid is amplified in a manner similar to that described in U.S. Pat. No. 4,683,195, and subsequent modifications of the procedure described therein.
  • sequence information from the ends of the region of interest or beyond are used to design oligonucleotide primers that are identical or similar in sequence to opposite strands of a potential template to be amplified.
  • a nucleic acid sequence can be amplified from RNA or DNA.
  • a nucleic acid sequence can be isolated by PCR amplification from total cellular RNA, total genomic DNA, and cDNA as well as from bacteriophage sequences, plasmid sequences, viral sequences, and the like.
  • reverse transcriptase can be used to synthesize complimentary DNA strands.
  • nucleic acid can be introduced into a cell.
  • many methods for introducing nucleic acid into cells are well known to those skilled in the art.
  • calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and viral-mediated nucleic acid transfer are common methods for introducing nucleic acid into cells.
  • naked DNA can be delivered directly to cells in vivo as describe elsewhere (U.S. Pat. Nos. 5,580,859 and 5,589,466 including continuations thereof).
  • nucleic acid can be introduced into cells by generating transgenic animals. It is noted that transgenic animals such as rabbits, goats, sheep, and cows can be engineered such that large amounts of a polypeptide are secreted into their milk.
  • Transgenic animals can be aquatic animals (such as fish, sharks, dolphin, and the like), farm animals (such as pigs, goats, sheep, cows, horses, rabbits, and the like), rodents (such as rats, guinea pigs, and mice), non-human primates (such as baboon, monkeys, and chimpanzees), and domestic animals (such as dogs and cats).
  • Several techniques known in the art can be used to introduce nucleic acid into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc.
  • nucleic acid that encodes a polypeptide can be maintained within a cell in any form.
  • nucleic acid can be integrated into the genome of a cell or maintained in an episomal state.
  • a cell can be a stable or transient transformant.
  • any method can be used to direct the expression of a particular polypeptide.
  • Such methods include, without limitation, constructing a nucleic acid such that a regulatory element promotes the expression of a nucleic acid sequence that encodes a polypeptide.
  • regulatory elements are DNA sequences that regulate the expression of other DNA sequences at the level of transcription.
  • regulatory elements include, without limitation, promoters, enhancers, and the like.
  • a conjugate to vaccinate rats can be designed to contain polypeptides having an N-terminal polyhistidine sequence followed by an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH4 domain, and a C-terminal polyhistidine sequence.
  • the first opossum IgE CH2 domain can be followed by three rat IgE CH3 domains as opposed to only one rat IgE CH3 domain. In either case, two polypeptides can be connected via disulfide bonds such that dimers are formed.
  • an anti-polyhistidine antibody can be used as a linking molecule to connect any number of single polypeptides or dimers through the N-terminal and C-terminal polyhistidine sequences.
  • three dimers can be linked sequentially via two anti-polyhistidine antibodies (i.e., dimer one connected to dimer two by antibody one, and dimer two connected to dimer three by antibody two).
  • mixing polypeptides with a linking molecule can result in a vaccine that contains vaccine conjugates with various sizes as well as various combinations of polypeptides.
  • a vaccine can contain a substantial amount of vaccine conjugates having less than four polypeptides with few having greater than four polypeptides. It is also noted that the general configuration of the polypeptides within a vaccine conjugate can be adapted to vaccinate mammals other than rats. For example, the rat IgE domains can be replaced with human IgE domains to vaccinate humans.
  • the invention provides vaccine conjugates that contain a polypeptide having a cytokine activity such that a potent immune response is induced against another polypeptide within the conjugate.
  • Such immune responses can be more potent than the responses induced by a conjugate lacking a polypeptide having a cytokine activity.
  • a vaccine conjugate containing polypeptide X and a polypeptide having a cytokine activity presumably concentrates cytokine activity to the localized area containing polypeptide X.
  • a vaccine conjugate containing a polypeptide having cytokine activity can stimulate cells that participate in generating a specific immune response against other polypeptides within a vaccine conjugate.
  • a polypeptide having cytokine activity can have any type of cytokine activity.
  • a polypeptide can have interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , TNF- ⁇ , IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, or granulocyte-macrophage colony stimulating factor (GM-CSF) activity.
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • a polypeptide having cytokine activity can be a polypeptide that is either naturally occurring or non-naturally occurring.
  • a naturally occurring polypeptide is any polypeptide having an amino acid sequence as found in nature, including wild-type and polymorphic polypeptides.
  • Such naturally occurring polypeptides can be obtained from any species including, without limitation, human, chimpanzee, baboon, rat, or mouse.
  • human interferon- ⁇ can be used in a vaccine conjugate.
  • a non-naturally occurring polypeptide is any polypeptide having an amino acid sequence that is not found in nature.
  • a non-naturally occurring polypeptide can be a mutated version of a naturally occurring polypeptide, or an engineered polypeptide.
  • a non-naturally occurring polypeptide having interferon- ⁇ activity can be a mutated version of a naturally occurring polypeptide having interferon- ⁇ activity that retains at least some interferon- ⁇ activity.
  • a polypeptide can be mutated by, for example, sequence additions, deletions, and/or substitutions using standard methods such as site-directed mutagenesis of the corresponding nucleic acid coding sequence.
  • a conjugate can contain any number of polypeptides having cytokine activity.
  • a conjugate can contain two polypeptides having cytokine activity.
  • a conjugate can contain polypeptides having different cytokine activities.
  • a conjugate can contain one polypeptide having interferon- ⁇ activity and another having GM-CSF activity.
  • polypeptides having cytokine activity can be obtained using any method.
  • a polypeptide having cytokine activity can be designed to contain a polyhistidine sequence such that affinity chromatography can be used to purify the polypeptide.
  • any method can be used to form a conjugate.
  • a polypeptide having cytokine activity can be designed to contain a linker site such that a linking molecule can link that polypeptide to another polypeptide such as any of the polypeptides described herein.
  • a conjugate to vaccinate rats can be designed to contain polypeptides having cytokine activity as well as polypeptides having an N-terminal polyhistidine sequence followed by an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH4 domain, and a C-terminal polyhistidine sequence.
  • the polypeptides having cytokine activity can contain an N-terminal polyhistidine sequence such that affinity chromatography can be used for purification.
  • an anti-polyhistidine antibody can be used as a linking molecule to connect any number of polypeptides via the polyhistidine sequences.
  • a conjugate can contain an interferon- ⁇ polypeptide followed by three polypeptides containing IgE domains followed be an interferon- ⁇ polypeptide with each connection being via an anti-polyhistidine antibody.
  • mixing polypeptides with a linking molecule can result in a vaccine that contains vaccine conjugates with various sizes and various combinations of polypeptides.
  • a vaccine can contain a substantial amount of vaccine conjugates having polypeptides with interferon- ⁇ activity with few having both polypeptides with interferon- ⁇ activity and polypeptides with interferon- ⁇ activity.
  • the general configuration of the polypeptides within a vaccine conjugate can be adapted to vaccinate mammals other than rats.
  • the rat IgE domains can be replaced with human IgE domains to vaccinate humans.
  • IgE surface epitopes For a successful IgE vaccination, it is essential to obtain a strong immune response that reacts predominantly with native IgE molecules (e.g., IgE surface epitopes). This is required in order to achieve efficient competition with the IgE receptor for free IgE, as the interaction between an IgE antibody and its specific IgE receptor is very strong (2.6 ⁇ 10 ⁇ 10 ; Froese A, CRC Crit. Rev. Immunol . 1:79-132 (1980)). As described herein, high levels of antibodies having specificity for self IgE antibodies were produced in rat strains by administering an immunogenic polypeptide. Several different rat strains were used including low, medium, and high IgE responders.
  • native IgE molecules e.g., IgE surface epitopes
  • an immunogenic polypeptide is a polypeptide that effectively induces an immune response in a mammal.
  • an immunogenic polypeptide can be a polypeptide that effectively induces an anti-self IgE response in a mammal.
  • immunogenic polypeptides contain at least one amino acid sequence (e.g., a single amino acid substitution) that would be considered non-self to a particular mammal.
  • immunogenic polypeptides that induce anti-self IgE responses can contain two components: a self IgE portion and a non-self IgE portion.
  • the self IgE portion can be responsible for conferring the specificity of the anti-self IgE response and the non-self IgE portion can serve to promote and stabilize the immunogenic polypeptide such that the specific anti-self IgE response is induced.
  • the self IgE portion of the immunogenic polypeptide is a portion of an IgE antibody that either directly interacts with an IgE receptor or indirectly influences the interaction of an IgE antibody with an IgE receptor.
  • the binding site for human IgE to the high affinity IgE receptor on mast cells and basophils is not located at the junction between the CH2 and CH3 domains of IgE as previously suggested, but instead is located in the N-terminal region of the CH3 domain. This region is, due to folding, located in the junction between the CH3 and CH4 domains of the native polypeptide.
  • use of the entire CH2-CH3 domain as a self IgE portion may potentially induce an anti-self IgE response with antibodies interacting with self IgE antibodies already bound to the surface of mast cells such that anaphylactic reactions occur.
  • the self IgE portion of an immunogenic polypeptide can be the entire CH3 domain without the CH2 domain.
  • the self IgE portion can be the N-terminal region of the CH3 domain.
  • the self IgE portion when vaccinating a rat, can be the N-terminal half of the rat CH3 domain in a context of a non-self IgE portion containing the entire CH2 domain of opossum IgE, the C-terminal half of the CH domain of opossum IgE, and the entire CH4 domain of opossum IgE.
  • Such an immunogenic polypeptide can be designated ORO-trunc (FIG. 2).
  • the non-self IgE portion of an immunogenic polypeptide stabilizes a functional conformation of the self IgE portion.
  • the self IgE portion is a CH3 domain
  • the non-self IgE portion could be a CH2 domain, a CH4 domain, or a CH2 and CH4 domain with the self CH3 domain being between the CH2 and CH4 domains.
  • the self IgE portion can be the rat CH3 domain in a context of a non-self IgE portion from, for example, opossum.
  • the rat CH3 domain can be located between the opossum CH2 and CH4 domains.
  • Such an immunogenic polypeptide can be designated ORO (FIG. 2).
  • the self IgE portion can be the mouse CH3 domain in a context of a non-self IgE portion from, for example, opossum.
  • Such an immunogenic polypeptide can be designated OMO (FIG. 2).
  • Immunogenic polypeptides of the invention can be produced using a eukaryotic expression system, such as a mammalian cell expression system.
  • the immunogenic polypeptide is soluble, properly folded, and properly modified such that an anti-self IgE response is induced upon administration to a mammal.
  • immunogenic polypeptides having one or more eukaryotic post-translational modifications can produce an anti-self IgE response that is significantly higher than similar polypeptides lacking eukaryotic post-translational modification (e.g., a bacterially produced polypeptide).
  • Eukaryotic post-translational modifications include, without limitation, glycosylation, acylation, limited proteolysis, phosphorylation, and isoprenylation.
  • soluble, properly folded, and properly modified immunogenic polypeptides can induce a strong anti-self IgE response in mammals with high concentrations of plasma IgE, so called high IgE responders.
  • Bacterially produced polypeptides are unable to produce such a strong anti-self IgE response in high IgE responders.
  • immunogenic polypeptides having high solubility, proper folding, and proper modification can be obtained and used as described herein to induce effective anti-self IgE responses in mammals.
  • the immunogenic polypeptides described herein can be used to treat mammals, including humans, that have high serum concentrations of IgE. It is noted that a high percentage of the severely allergic patients in the human population belong to this category of patients.
  • the IgE CH3 domain, or a portion of an IgE CH3 domain, derived from an organism to be vaccinated such as human can be inserted into the structural context of a distantly related IgE molecule such as an IgE molecule from a non-placental mammal (e.g., opossum, platypus, koala, kangaroo, wallaby, and wombat).
  • IgE antibodies from the grey short tailed opossum, a marsupial exhibit about 25 percent sequence identity with human, rat, pig, and dog IgE antibodies.
  • regions of the opossum IgE antibody can be used as the non-self IgE portion of an immunogenic polypeptide such that a potent anti-self IgE response is induced in a human, rat, pig, or dog.
  • a nucleic acid molecule for expressing an immunogenic polypeptide can be produced by splicing a first nucleic acid that encodes a portion of an IgE antibody from an organism to be vaccinated into a second nucleic acid that encodes a portion of an IgE antibody from a mammal distantly related to the organism to be vaccinated.
  • a nucleic acid molecule encoding an immunogenic polypeptide containing the CH3 domain of rat, human, pig, or dog IgE can be spliced into a nucleic acid containing the CH2 and CH4 domains of opossum IgE.
  • Such chimeric nucleic acid molecules can be constructed using common molecular cloning techniques.
  • nucleic acid such that the CH3 domain of an IgE antibody from one organism is positioned between the CH2 and CH4 domains of an IgE antibody from another organism results in a nucleic acid molecule that encodes a chimeric IgE molecule that has the CH3 domain in a structural context very similar to its native position within native IgE antibodies.
  • the opossum CH2 and CH4 domains can serve as the non-self IgE portion of the immunogenic polypeptide, since there is about 30 percent amino acid identity between opossum CH2 and CH4 domains and the corresponding domains of rat, human, dog, and pig IgE (FIG. 1).
  • Such immunogenic polypeptides can be produced in a mammalian host.
  • the resulting immunogenic polypeptides can be secreted from the mammalian producer cells in a properly folded and properly glycosylated form.
  • analysis, in the Biacore system. with monoclonal antibodies directed against the CH3 domain of human IgE revealed that these monoclonal antibodies can bind strongly to immunogenic polypeptides of the invention, indicating that the entire CH3 domain can be properly folded.
  • immunogenic polypeptides described herein can be such that deleterious side-effects are not exhibited, even in mammals that have highly elevated IgE titres prior to vaccination.
  • vaccination with an immunogenic polypeptide as described herein can induce an anti-self IgE response that is directed against the entire free pool of IgE.
  • Such a response is not limited to a specific allergen.
  • these methods and materials can be used to treat human allergies having a large variety of different atopic allergies.
  • a vaccine conjugate can contain a blocking molecule that inhibits the interaction between an antibody (e.g., an IgG antibody) and an Fc-gamma receptor II (e.g., CD32).
  • blocking molecules i.e., Fc-gamma receptor II blocking molecules
  • Anti-CD32 antibodies can be obtained using common antibody production and screening techniques.
  • Fc-gamma receptor II blocking molecules can be used in combination with any immunogenic polypeptide such that the immune response against the immunogenic polypeptide is enhanced.
  • a mixture containing an anti-CD32 antibody and an immunogenic polypeptide either conjugated or not can be administered to a mammal to induce a potent immune response against the immunogenic polypeptide.
  • an effective amount of any vaccine, vaccine conjugate, or immunogenic polypeptide described herein can be administered to a host.
  • An effective amount refers to any amount that induces a desired immune response while not inducing significant toxicity to the host. Such an amount can be determined by assessing a host's immune response after administration of a fixed amount of a particular material (e.g., immunization polypeptide).
  • the level of toxicity if any, can be determined by assessing a host's clinical symptoms before and after administering a fixed amount of a particular material. It is noted that the effective amount of a particular material administered to a host can be adjusted according to desired outcomes as well as the host's response and level of toxicity. Significant toxicity can vary for each particular host and depends on multiple factors including, without limitation, the host's disease state, age, and tolerance to pain.
  • any of the materials described herein can be administered to any part of the host's body including, without limitation, the joints, blood stream, lungs, intestines, muscle tissues, skin, and peritoneal cavity.
  • a vaccine conjugate can be administered by intravenous, intraperitoneal, intramuscular, subcutaneous, intrathecal, and intradermal injection, by oral administration, by inhalation, or by gradual perfusion over time.
  • an aerosol preparation containing an immunogenic polypeptide can be given to a host by inhalation.
  • the duration of vaccination with any of the materials described herein can be any length of time from as short as one day to as long as a lifetime (e.g., many years).
  • an immunogenic polypeptide can be administered once a year over a period of ten years. It is also noted that the frequency of treatment can be variable. For example, an immunogenic polypeptide can be administered once (or twice, three times, etc.) daily, weekly, monthly, or yearly.
  • Preparations for administration can include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents include, without limitation, propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters.
  • Aqueous carriers include, without limitation, water as well as alcohol, saline, and buffered solutions. Preservatives, flavorings, and other additives such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases, and the like may also be present. It will be appreciated that any material described herein that is to be administered to a mammal can contain one or more commonly known pharmaceutically acceptable carriers.
  • Any method can be used to determine if a particular immune response is induced.
  • antibody responses against particular antigens can be determined using immunological assays (e.g., ELISA).
  • clinical methods that can assess the degree of a particular disease state can be used to determine if a desired immune response is induced.
  • Nucleic acid molecules were constructed to encode immunogenic polypeptides containing both self and non-self IgE portions. These nucleic acid molecules were then used to synthesize soluble immunogenic polypeptides in mammalian cells. Such immunogenic polypeptides effectively induced a polyclonal anti-self IgE response upon administration to a mammal. In addition, the immunogenic polypeptides appear to be folded and glycosylated in a manner that enabled the immunogenic polypeptides to produce a strong and specific anti-self IgE response that was more potent than bacterially produced polypeptides lacking the non-self IgE portion.
  • the immunogenic polypeptides described herein contain a majority of the surface epitopes in the same conformation as in native plasma IgE. Moreover, immunogenic polypeptides containing a self IgE portion limited to either the entire CH3 domain or a fragment of the CH3 domain (e.g., N-terminal region of CH3) reduced the potential of producing anaphylactic antibodies within a mammal.
  • a ⁇ 330 base pair PCR fragment encoding the CH3 domain of rat IgE (Hellman L et al., Nucleic Acids Res .10:6041-6049 (1982)) was fused with two similar sized fragments encoding the CH2 and CH4 domains of opossum IgE (Aveskogh M and Hellman L, Eur. J Immunol ., 28:2738-2750 (1998)) by ligation into a modified version of the pCEP4 expression vector, pCEP-Pu2 (Margolskee R F et al., Mol. Cell Biol . 8:2837-2847 (1988)).
  • This vector contains the CMV promoter-enhancer, located directly 5′ of the coding region of interest and allows high levels of expression in mammalian cells.
  • This vector also contains the coding regions for puromycin resistance and the EBV EBNA1 gene.
  • the EBNA1 gene confers maintenance of stable replicating-episomal copies of the vector in human or canine cell lines.
  • the nucleic acid molecule containing the opossum IgE CH2, rat IgE CH3, and opossum IgE CH4 nucleic acid sequences also contained nucleic acid sequences that encode a signal sequence and six histidine residues at the N-terminal region.
  • the region containing the signal sequence and six histidine residues facilitates secretion of the encoded polypeptide from producer cells and enables polypeptide purification with Ni ++ -chelating columns.
  • the opossum CH2-IgE/rat CH3-IgE/opossum CH4-IgE (ORO) immunogenic polypeptide was purified from 293 cell conditioned media on a nickel-chelating column to about 100 percent purity. Following elution of the ORO immunogenic polypeptide with a solution containing 20 mM Tris (pH 8.0), 0.1 M NaCl, and 100 mM imidazole, the eluate was dialyzed against PBS (pH 7.5) overnight at 4° C. The ORO immunogenic polypeptide was then concentrated to about 2 mg/mL using an Amicon concentrator.
  • This purified ORO immunogenic polypeptide preparation was used as the active component of an anti-self IgE vaccine for treating rats.
  • Each rat was sensitized to ovalbumin as follows. Ten (10) ⁇ g of ovalbumin in PBS was administered to each rat intraperitoneally. Three weeks after this initial intraperitoneal injection of ovalbumin, the rats received weekly intraperitoneal injections of 1 ⁇ g of ovalbumin for four weeks. During this four week period, the rats became sensitized to ovalbumin obtaining a total IgE and ovalbumin-specific IgE response that was high and persistent. After this four week-period, the rats started a vaccination program. During the entire vaccination program, intraperitoneal injections of ovalbumin continued as follows. During the first two weeks of vaccination, the rats received intraperitoneal injections of 1 ⁇ g of ovalbumin weekly. After the first two weeks of vaccination, the rats received intraperitoneal injections of 1 ⁇ g of ovalbumin every other week.
  • each rat received intraperitoneal injections of about 250 ⁇ g of antigen (either the ORO immunogenic polypeptide or BSA) dispersed in 0.2 mL of a 50:50 solution of Freund's complete adjuvant and PBS.
  • the rats were given a booster injection containing about 100 ⁇ g of antigen dispersed in 0.1 mL of a 50:50 solution of Freund's incomplete adjuvant and PBS.
  • the rats were given an additional booster identical to the first booster.
  • blood samples were taken and measured in an ELISA as follows.
  • the level of IgG anti-IgE antibodies directed against self rat IgE was measured by an ELISA.
  • Native rat IgE was used at a concentration of 5 ⁇ g/mL for coating the ELISA plates. Successive 1/5 dilutions of serum from each of the individual rats were tested by color reaction in the ELISA.
  • the presence of rat IgG antibodies having specificity for rat IgE antibodies was determined using two biotinylated mouse monoclonal antibodies, one with specificity for rat IgG2a/b and one for rat IgG1. Alkaline phosphatase coupled strepavidin was used to detect these biotinylated mouse monoclonal antibodies.
  • Purified monoclonal rat IgE (IR 162) was used to coat the ELISA plates (5 ⁇ g/mL) and two biotinylated mouse monoclonal antibodies were used to detect rat IgG anti-IgE antibodies. Following the second booster dose, high anti-IgE titres were detected in the low, medium, and high IgE responding rats that received the vaccine containing the ORO immunogenic polypeptide. Anti-IgE titers were not detected in rats treated with the BSA control. Thus, the ORO immunogenic polypeptide was capable of inducing an anti-self IgE response in rats that contained low, medium, and high amounts of IgE antibodies.
  • Wistar rats were used. Wistar rats are medium IgE responders. The anti-self IgE response produced by the Wistar rats was similar to the response observed in the Lewis rats.
  • a recombinant polypeptide (OOO) containing the opossum CH2-CH3-CH4 domains was injected into the Wistar strain. After a second booster injection, sera from these rats were collected and tested for the presence of antibodies having specificity for rat IgE. No anti-rat IgE antibodies were detected in the rats treated with the OOO polypeptide (FIG. 4).
  • Wistar rats treated with the ORO immunogenic polypeptide exhibited an anti-self IgE response similar to that observed in Lewis rats.
  • Wistar rats treated with a recombinant polypeptide (PPP) containing platypus CH2-CH3-CH4 domains did not produce an anti-rat IgE response.
  • PPPP recombinant polypeptide
  • nucleic acid construct encoding the ORO immunogenic polypeptide described in Example 2 was used to produce two polypeptides each having several identical self epitopes.
  • One polypeptide contained two identical clusters of self epitopes (the entire rat CH3 domain), while the other polypeptide contained four such clusters.
  • nucleic acid encoding six histidine residues was added to the C-terminal end of the opossum CH4 domain by including a nucleotide sequence for six histidine residues in the 3′ PCR primer.
  • each polypeptide contained a polyhistidine sequence at both the N- and C-terminal ends so that conjugates can be formed.
  • a nucleic acid fragment encoding the opossum CH2 and the rat CH3 domains of the original construct was obtained by PCR amplification. This fragment was subsequently ligated into the construct encoding the ORO immunogenic polypeptide. The resulting construct encoded a polypeptide designated ORORO.
  • This ORORO polypeptide contains two rat CH3 domains, two opossum CH2 domains, and one opossum CH4 domain in the following order opossum CH2, rat CH3, opossum CH2, rat CH3, and opossum CH4. Thus, this polypeptide has two identical CH3 domains, each with multiple self epitopes.
  • the nucleic acid construct encoding ORORO was used as starting material to produce the second immunogenic polypeptide.
  • This polypeptide contains two additional rat CH3 domains that were added to a position 3′ of the first rat CH3 domain in the ORORO polypeptide.
  • the resulting polypeptide has a polyhistidine tag followed by an opossum CH2 domain, three identical rat CH3 domains, one opossum CH2 domain, one rat CH3 domain, an opossum CH4 domain, and a C-terminal polyhistidine tag (6his-ORRRORO-6his).
  • each recombinant polypeptide was produced in the pCEP4 based vector system.
  • the polypeptides were purified using Ni ++ chelating columns according to the method described in Example 2.
  • Similar vaccine constructs are produced using dog or human IgE CH3 domain instead of the rat IgE CH3 domain.
  • the purified polypeptides of Example 7 are mixed with a monoclonal anti-polyhistidine antibody in various combinations ranging from a 1/1 to a 10/1 ratio (polypeptide to monoclonal antibody ratio). This mixture results in the generation of long multimeric conjugates with a large number of identical self epitopes in tandem. The biological activity of the various combinations is assessed in rats as described herein. The non-conjugated ORO immunogenic polypeptide is used as a reference to assess immune responses.
  • PCR primers are designed so that cDNAs encoding rat, dog, and human cytokines (e.g., interferon- ⁇ , interferon- ⁇ , and GM-CSF) can be isolated from total spleen mRNA.
  • the nucleotide sequence encoding six histidine residues is introduced into each 5′ PCR primer so that the cytokines can be purified via affinity chromatography and can be non-covalently conjugated to the polypeptides described herein via an anti-polyhistidine antibody.
  • the recombinant cytokines are produced using any one of the following three expression systems: bacteria, yeast (e.g., Pichia pastoris ), and mammalian cells (e.g., 293-EBNA cells using a pCEP-4 based expression system).
  • bacteria e.g., Bacillus subtilis
  • yeast e.g., Pichia pastoris
  • mammalian cells e.g., 293-EBNA cells using a pCEP-4 based expression system.
  • Cytokines produced according to Example 9 are used to make vaccine conjugates.
  • a mixture of three different cytokines e.g., mouse interferon- ⁇ , rat interferon- ⁇ and rat GM-CSF
  • ORORO polypeptide e.g., mouse interferon- ⁇ , rat interferon- ⁇ and rat GM-CSF
  • cytokine to immunogenic polypeptide ratio a mixture of 1/10 ratio (cytokine to immunogenic polypeptide ratio) is tested. With three cytokines, this ratio results in a mixture of 30% cytokine per molar basis and 70% immunogenic polypeptide. In addition, this mixture contains an anti-polyhistidine antibody at a 1/10 ratio (immunogenic polypeptide to monoclonal antibody ratio). A large number of ratio combinations is evaluated so that an optimal cytokine to immunogenic polypeptide ratio as well as an optimal monoclonal antibody to immunogenic polypeptide ratio is determined. In addition, polypeptides having cytokine activity from various species is assessed to determine the optimal combination for a particular species.

Abstract

The invention relates to methods and materials involved in the treatment and prevention of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal. In addition, the invention provides vaccine conjugates, immunogenic polypeptides, nucleic acid molecules that encode immunogenic polypeptides, host cells containing the nucleic acid molecules that encode immunogenic polypeptides, and methods for making vaccine conjugates and immunogenic polypeptides as well as nucleic acid molecules that encode immunogenic polypeptides. Further, the invention provides an IgE vaccine that induces an anti-self IgE response in a mammal.

Description

    RELATED APPLICATIONS
  • This application claims priority from U.S. Provisional Application Serial No. 60/106,652, filed Nov. 2, 1998.[0001]
    • BACKGROUND
  • 1. Technical Field [0002]
  • The invention relates to methods and materials involved in the treatment of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal. [0003]
  • 2. Background Information [0004]
  • Mammals are susceptible to many diseases and illnesses including bacterial infections, viral infections, and IgE-related diseases such as allergies. In general, infections are characterized by the invasion and multiplication of microorganisms (e.g., bacteria, fungi, and viruses) within body tissues. Many types of infections can be treated or prevented by the use of vaccines. For example, the polio vaccine can prevent poliovirus infections. Typically, a vaccine is a suspension of attenuated or killed microorganisms. [0005]
  • IgE-related diseases are mediated by a class of immunoglobulin designated as immunoglobulin E (IgE). In fact, IgE antibodies are a major cause of hypersensitivity reactions found within the human population despite their normally very low concentration in human plasma (10-400 ng/mL). The effects are due to the interaction of IgE antibodies with the high-affinity receptor for IgE on mast cells and basophilic leukocytes. Cross-linking of two IgE receptors on the surface of these cell types, for example by allergen binding, initiates the release of a number of physiologically active substances such as histamine, PAF (platelet activating factor), heparin, leukotrienes, prostaglandins, thromboxanes, and chemotactic factors for eosinophilic and neutrophilic granulocytes. Presumably, these mediators cause the direct symptoms of IgE-mediated allergic reactions (type I hypersensitivity). Disease conditions belonging to this-group can include asthma, fur allergies, pollen allergies, food allergies, and eczema. [0006]
  • The high-affinity receptor for IgE has been characterized. This receptor appears to be present on mast cells, basophilic leucocytes, eosinophils, monocytes, and Langerhan cells. In addition, the receptor is a complex of three different subunits (α, β, and γ chains). The α chain is localized mainly extra-cellularly and appears to interact with the IgE molecule. Previous studies of the epsilon chain of the IgE molecule have suggested that a region of 76 amino acids at the border between the CH2 and CH3 domains (CH refers to the constant domains in the heavy chain) is important for the interaction between the IgE molecule and its high-affinity receptor. In addition, a peptide corresponding to this region was shown to inhibit the interaction between native IgE and its high-affinity receptor in vitro at a molar ratio of nearly 1:1 compared to the whole CH2-CH3-CH4 region (Helm et al., [0007] Nature 331, 180-183 (1988)). This peptide was also shown to inhibit an IgE-mediated flare reaction in allergen stimulation. In this case, however, the concentration was about 10 times the concentration needed to exhibit the same inhibitory effect with native IgE (Helm et al., Proc. Natl. Acad Sci. USA 86, 9465-9469 (1989)).
    • SUMMARY
  • The invention relates to methods and materials involved in the treatment and prevention of various diseases such as infections and IgE-related diseases. Specifically, the invention relates to methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal. Such methods and materials can be used to treat atopic allergies in mammals such as humans, dogs, and pigs. [0008]
  • The invention is based on the discovery that a vaccine conjugate can be designed to contain at least two polypeptides with each polypeptide having at least two similar amino acid segments such that the administration of the conjugate to a mammal can induce an immune response against at least a portion of one of the polypeptides. Such immune responses can be more potent than the responses induced by any of the polypeptides in an unconjugated form or any conjugate of polypeptides lacking at least two similar amino acid segments. Thus, the vaccine conjugates described herein can be used to provide mammals with substantial protection against a wide range of either self (e.g., IgE molecules) or non-self (e.g., viral polypeptides) antigens. [0009]
  • The invention also is based on the discovery that a vaccine conjugate can be designed to contain a polypeptide having a cytokine activity such that a potent immune response is induced against another polypeptide within the conjugate. Such immune responses can be more potent than the responses induced by a conjugate lacking a polypeptide having a cytokine activity. Although not limited to any particular mode of action, a conjugate containing a polypeptide having a cytokine activity as well as an immunogenic polypeptide presumably concentrates cytokine activity to the localized area containing the immunogenic polypeptide. Thus, the polypeptide having cytokine activity can stimulate cells that participate in generating a specific immune response against the immunogenic polypeptide. [0010]
  • In addition, the invention is based on the discovery that polypeptides containing a self IgE portion and a non-self IgE portion are immunogenic and induce an effective anti-self IgE response in mammals. Such immunogenic polypeptides can be used as a vaccine to induce an anti-self IgE response that counteracts the hypersensitivity induced by self IgE antibodies. Although not limited to any particular mode of action, the immunogenic polypeptides described herein induce the production of anti-self IgE antibodies that presumably have specificity for the portion of the IgE molecule that interacts with the high-affinity IgE receptor. After production, the anti-self IgE antibodies can interact with the self-IgE antibodies such that the self IgE antibodies are unable to bind to the high-affinity IgE receptor. This inhibition of receptor binding presumably reduces the hypersensitivity induced by self IgE antibodies. Thus, the degree of IgE-induced effects can be reduced as more anti-self IgE antibodies are produced. [0011]
  • In general, the invention features an immunogenic polypeptide having a self IgE portion and a non-self IgE portion. The immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal (e.g., human). The self portion can contain at least a portion of a CH3 domain of IgE. The polypeptide can be capable of dimerizing to form a soluble immunogenic dimer effective to induce the anti-self IgE response in the mammal. The non-self IgE portion can contain a first region and a second region with the self IgE portion being located between the first and second regions of the non-self IgE portion. The first region can contain at least a portion of an IgE CH2 domain, and the second region can contain at least a portion of an IgE CH4 domain. The non-self IgE portion can contain an IgE sequence present in a non-placental mammal (e.g., opossum, platypus, koala, kangaroo, wallaby, and wombat). The self IgE portion can lack the CH2 domain of an IgE antibody. The immunogenic polypeptide can contain a eukaryotic post-translational modification. In addition, the immunogenic polypeptide can contain a polyhistidine sequence. The anti-self IgE response can be a polyclonal response. [0012]
  • In another embodiment, the invention features a nucleic acid molecule containing a nucleic acid sequence that encodes an immunogenic polypeptide. The immunogenic polypeptide contains a self IgE portion as well as a non-self IgE portion, and is effective to induce an anti-self IgE response in a mammal. The nucleic acid molecule can contain an additional nucleic acid sequence that encodes an amino. acid sequence that promotes the secretion of the immunogenic polypeptide from a eukaryotic cell. [0013]
  • Another embodiment of the invention features a host cell (e.g., eukaryotic cell) containing a nucleic acid molecule that has a nucleic acid sequence that encodes an immunogenic polypeptide. The immunogenic polypeptide contains a self IgE portion as well as a non-self IgE portion, and is effective to induce an anti-self IgE response in a mammal. [0014]
  • Another embodiment of the invention features a soluble immunogenic dimer containing two immunogenic polypeptides that are capable of dimerizing to form the soluble immunogenic dimer. Each of the two immunogenic polypeptides contains a self IgE portion and a non-self IgE portion, and the soluble immunogenic dimer is effective to induce an anti-self IgE response in a mammal. [0015]
  • Another embodiment of the invention features a vaccine containing an immunogenic polypeptide having a self IgE portion and a non-self IgE portion. The immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal. The vaccine can contain a pharmaceutically acceptable carrier. [0016]
  • Another embodiment of the invention features a method for making a nucleic acid molecule that encodes an immunogenic polypeptide effective to induce an anti-self IgE response in a mammal. The method includes combining first and second nucleic acid sequences to form the nucleic acid molecule, where the first nucleic acid sequence encodes at least a portion of an IgE molecule present within the mammal, and where the second nucleic acid sequence encodes at least a portion of an IgE molecule not present in the mammal. [0017]
  • Another embodiment of the invention features a method for making a nucleic acid molecule that encodes an immunogenic polypeptide effective to induce an anti-self IgE response in a mammal. The method includes (a) selecting a first nucleic acid sequence, where the first nucleic acid sequence encodes at least a portion of an IgE molecule present within the mammal, (b) selecting a second nucleic acid sequence, where the second nucleic acid sequence encodes at least a portion of an IgE molecule not present in the mammal, and (c) combining the first and second nucleic acid sequences to form the nucleic acid molecule. [0018]
  • In another aspect, the invention features a vaccine complex for vaccinating a mammal (e.g., human). The complex contains a first and second polypeptide. Each of the first and second polypeptides contains at least two similar amino acid sequences at least five amino acid residues in length. In addition, the first and second polypeptides are connected to form the complex, and administration of the complex to the mammal induces an immune response against at least a portion of the first or second polypeptide. The first and/or second polypeptide can contains an amino acid sequence expressed by the mammal. The first and second polypeptides can be identical, and can form a dimer. The connection of the first and second polypeptides can include a disulfide bond. The connection of the first and second polypeptides can include a non-covalent interaction. The first and/or second polypeptide can contain a linker site (e.g., a polyhistidine sequence). The amino and carboxyl termini of the first and/or second polypeptide can contain the linker site. The complex can include a linking molecule (e.g., an antibody such as an anti-polyhistidine antibody). A linking molecule can connects the first and second polypeptide. The complex can contain a third polypeptide, where the third polypeptide has a cytokine activity. The cytokine activity can be an activity of a cytokine such as interferon-α, interferon-β, interferon-γ, TNF-α, IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, and granulocyte-macrophage colony stimulating factor. A linking molecule can connect the third polypeptide to the first or second polypeptide. The similar amino acid sequences can be greater than about twenty amino acid residues in length. The complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody). [0019]
  • In another embodiment, the invention features a vaccine complex for vaccinating a mammal (e.g., human). The complex contains a first polypeptide connected to a second polypeptide, where the first polypeptide contains at least two similar amino acid sequences at least five amino acids in length. In addition, the second polypeptide has a cytokine activity, and administration of the complex to the mammal induces an immune response against at least a portion of the first polypeptide. The first polypeptide can contain an amino acid sequence expressed by the mammal. The connection of the first and second polypeptides can include a non-covalent interaction. The first and/or second polypeptide can contain a linker site (e.g., a polyhistidine sequence). For example, the amino and carboxyl termini of the first polypeptide can contain a linker site. The complex can contain a linking molecule (e.g., an antibody such as an anti-polyhistidine antibody). The cytokine activity can be an activity of a cytokine such as interferon-α, interferon-β, interferon-γ, TNF-α, IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, and granulocyte-macrophage colony stimulating factor. The complex can contain a third polypeptide. The first and third polypeptides can be identical and can form a dimer. The connection of the first and third polypeptides can include a disulfide bond. The similar amino acid sequences can be greater than about twenty amino acid residues in length. The complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody). [0020]
  • Another embodiment of the invention features a vaccine complex for vaccinating a mammal (e.g., human). The complex contains a first, second, and third polypeptide, where the first, second, and third polypeptides are connected to form the complex. The first polypeptide has a first cytokine activity. The second polypeptide has a second cytokine activity. The administration of the complex to the mammal induces an immune response against at least a portion of the third polypeptide. The third polypeptide can contain an amino acid sequence expressed by the mammal. The connections of the first, second, and third polypeptides can include non-covalent interactions. The first, second, and/or third polypeptide can contain a linker site. The complex can contain a linking molecule. The third polypeptide can contain at least two similar amino acid sequences at least five amino acids in length. The complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody). [0021]
  • Another embodiment of the invention features a vaccine complex for vaccinating a mammal (e.g., human). The complex contains a first polypeptide connected to a second polypeptide, where the first polypeptide is a polypeptide having interferon-α or interferon-β activity, and administration of the complex to the mammal induces an immune response against at least a portion of the second polypeptide. The second polypeptide can contain an amino acid sequence expressed by the mammal. The connection of the first and second polypeptides can include a non-covalent interaction. The first and/or second polypeptide can contain a linker site. The complex can contain a linking molecule. The second polypeptide can contain at least two similar amino acid sequences at least five amino acids in length. The complex can contain an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody). [0022]
  • Another aspect of the invention features a vaccine for vaccinating a mammal (e.g., human). The vaccine contains an Fc-gamma receptor II blocking molecule (e.g., an anti-CD32 antibody) and a polypeptide, where administration of the vaccine to the mammal induces an immune response against at least a portion of the polypeptide. The polypeptide can contain an amino acid sequence expressed by the mammal. The Fc-gamma receptor II blocking molecule and polypeptide can be connected, and the connection can include a non-covalent interaction. [0023]
  • Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. [0024]
  • Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.[0025]
    • DESCRIPTION OF DRAWINGS
  • FIG. 1 is a diagram comparing the amino acid sequences of the CH2-CH3-CH4 domains of human, rat, and opossum IgE, in the upper, middle, and lower rows, respectively. The opossum sequence also contains an N-terminal signal sequence followed by six histidine residues. [0026]
  • FIGS. [0027] 2A-B contain diagrams comparing the amino acid sequences of various polypeptides containing the following components: opossum CH2—rat CH3—opossum CH4 (ORO); opossum-CH2—rat N-term CH3—opossum C-term CH3—opossum CH4 (ORO-trunc); opossum CH2—mouse CH3—opossum CH4 (OMO); opossum CH2—CH3—CH4 (OOO); platypus CH2—CH3—CH4 (PPP); opossum CH2—human CH3—opossum CH4 (OHO); opossum CH2—pig CH3—opossum CH4 (OPO); and opossum CH2—dog CH3—opossum CH4 (ODO). The arrows indicate domain borders.
  • FIGS. [0028] 3A-C contain diagrams depicting the analysis of immune responses against an ORO immunogenic polypeptide in a panel of three different strains of rats. The level of rat IgG anti-IgE antibodies directed against native rat IgE was measured by an ELISA. Native rat IgE was used at a concentration of 5 μg/mL for coating of ELISA plates. Successive 1/5 dilutions of serum from each of the individual rats were tested by color reaction in the ELISA. Six vaccinated rats were analyzed together with four control rats from each strain.
  • FIG. 4 is a diagram depicting an analysis of the immune responses against an ORO immunogenic polypeptide as well as OOO and PPP control polypeptides.[0029]
    • DETAILED DESCRIPTION
  • The invention provides methods and materials for the treatment of various diseases such as infections and IgE-related diseases. Specifically, the invention provides methods and materials that can be used to vaccinate a mammal against specific self or non-self antigens. For example, the methods and materials described herein can be used to reduce the effects of IgE antibodies within a mammal by reducing the amount of total and receptor bound IgE antibodies in the mammal. [0030]
  • 1. Vaccine Conjugates [0031]
  • The invention provides vaccine conjugates that contain at least two polypeptides with each of those polypeptides having at least two similar amino acid segments. The term “conjugate” as used herein refers to any composition containing at least two polypeptides that are directly or indirectly connected via one or more covalent or non-covalent bonds. For example, a conjugate can contain ten sequentially connected polypeptides (e.g., number one is connected to number two, number two is connected to number three, number three is connected to number four, etc.). The term “connected” as used herein with respect to polypeptides refers to any type of covalent or non-covalent bond including, without limitation, single bonds, double bonds, triple bonds, disulfide bonds, hydrogen bonds, hydrophobic interactions, van der Waals interactions, and any combination thereof. For example, a disulfide bond can connect polypeptide number one to polypeptide number two. Alternatively, an antibody can connect polypeptide numbers one and two. In this case, polypeptides one and two each would contain an epitope recognized by the antibody such that the resulting conjugate contains polypeptide number one non-covalently connected to the antibody which is non-covalently connected to polypeptide number two. It is noted that polypeptide numbers one and two in this example can have an identical amino acid sequence. [0032]
  • The term “amino acid segment” as used herein refers to a contiguous stretch of amino acid sequence within a polypeptide. For example, the amino acid sequence from [0033] residues 30 to 40 within a 100 amino acid polypeptide would be considered an amino acid segment. For the purpose of this invention, an amino acid segment can be any length greater than about five amino acid residues (e.g., greater than about six, seven, eight, nine, ten, 15, 20, 25, 30, 40, 50, 75, 100, 150, or 200 amino acid residues). Thus, an amino acid segment can be the entire CH3 domain of an IgE antibody.
  • The term “similar” as used herein with respect to at least two amino acid segments means the segments are at least about 50 percent identical in amino acid sequence. For example, similar amino acid segments can be about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100 percent identical. For the purpose of this invention, the percent amino acid sequence identity between one amino acid segment and another is calculated as follows. First, the amino acid sequences of the two amino acid segments are aligned using the MEGALIGN® (DNASTAR, Madison, Wis., 1997) sequence alignment software following the Jotun Heim algorithm with the default settings. Second, the number of matched positions between the two aligned amino acid sequences is determined. A matched position refers to a position in which identical residues occur at the same position as aligned by the MEGALIGN® sequence alignment software. Third, the number of matched positions is divided by the total number of positions, and the resulting value multiplied by 100 to obtain the percent identity. [0034]
  • Again, a vaccine conjugate of the invention contains at least two polypeptides with each of those polypeptides having at least two similar amino acid segments. Thus, a vaccine conjugate can contain two, three, four, five, six, seven, eight, nine, ten, 15, 20, 25, or 30 polypeptides with each having at least two similar amino acid segments. It is noted that a polypeptide containing at least two similar amino acid segments can contain two, three, four, five, six, seven, eight, nine, ten, or more similar amino acid segments. In addition to the polypeptides containing at least two similar amino acid segments, a vaccine conjugate of the invention can contain any number of polypeptides not having at least two similar amino acid segments. For example, a vaccine conjugate can contain four polypeptides each having a 30 amino acid residue segment repeated three times as well as two polypeptides each lacking similar amino acid segments. [0035]
  • Typically, a vaccine conjugate contains a polypeptide that will act as an antigen against which an immune response is desired. Thus, a vaccine conjugate within the scope of the invention can contain any type of polypeptide including, without limitation, bacterial polypeptides, fungal polypeptides, viral polypeptides, and mammalian polypeptides. For example, a vaccine conjugate can contain five hepatitis C virus polypeptides. It is noted that each polypeptide of a conjugate can have an identical amino acid sequence. In addition, a polypeptide of a vaccine conjugate typically contains similar amino acid segments each of which can act as a defined antigenic unit against which an immune response is desired. Thus, a polypeptide of a vaccine conjugate can contain similar amino acid segments that correspond to any region from a polypeptide including, without limitation, receptor binding regions, ligand binding regions, enzyme active sites, enzyme cleavage sites of polypeptide substrates, antigen-binding regions of antibodies, and epitopes recognized by antibodies. For example, a polypeptide of a vaccine conjugate can contain three similar amino acid segments that each correspond to the enzyme active site of enzyme X. It is noted that similar amino acid segments can be in tandem or dispersed throughout a polypeptide. Typically, the administration of a vaccine conjugate results in the formation of antibodies having specificity for an epitope formed by at least a portion of the similar amino acid segments within one of the polypeptides of the vaccine conjugate. [0036]
  • Any method can be used to make the polypeptides of a vaccine conjugate including, without limitation, prokaryotic expression systems, eukaryotic expression systems, and chemical synthesis techniques. In addition, a polypeptide of a vaccine conjugate can be obtained from natural tissue sources. For example, a brain glycopolypeptide can be obtained from brain tissue. Typically, each different polypeptide of a conjugate is made independently, or isolated independently, and then used to form a conjugate. It is noted that polypeptides can be purified prior to being used to form a conjugate. Any method can be used to purify polypeptides including, without limitation, fractionation, centrifugation, and chromatography. For example, polypeptides containing a polyhistidine sequence can be purified using affinity chromatography. Once obtained, the polypeptides can be connected using any method. For example, a polypeptide sample can be incubated with a linking molecule such that individual polypeptides form conjugates. A linking molecule is any molecule that connects two polypeptides. Typically, a linking molecule is a molecule with two reactive groups or sites that are capable of interacting with and thereby forming a link between amino acid residues from two polypeptides. A linking molecule can be a specific linking molecule such as an antibody or a non-specific linking molecule such as a chemical reagent (e.g., glutaraldehyde and formaldehyde). [0037]
  • Any antibody can be used as a linking molecule. For example, an anti-polyhistidine antibody or an anti-epitope tag antibody such as an anti-FLAG® epitope antibody or anti-hemagglutinin (HA) tag antibody can be used to connect two polypeptides. FLAG® epitopes are described in U.S. Pat. Nos. 4,703,004 and 4,782,137. It is noted that the polypeptides to be connected with a specific linking molecule need to contain the specific site recognized by the linking molecule. For example, to connect two polypeptides with an anti-polyhistidine antibody, each polypeptide must contain the polyhistidine epitope recognized by that antibody. For the purpose of this invention, the specific site recognized by a specific linking molecule such as an antibody is referred to as a linker site. Any method can be used to make a polypeptide that contains a linker site such that a particular antibody can be used as a linking molecule. For example, common molecular cloning techniques can be used to introduce the nucleic acid that encodes a FLAG tag epitope into the nucleic acid that encodes a particular polypeptide. It is noted that a linker site can be located at any position. For example, a polyhistidine sequence can be at the N-terminus, C-terminus, or an internal position of a polypeptide. In addition, a polypeptide can contain more than one linker site. For example, a polypeptide can have a polyhistidine sequence at an internal position as well as at the C-terminus. Further, a polypeptide can contain different linker sites. For example, a polypeptide can have a polyhistidine sequence at an internal position and a FLAG tag epitope at the C-terminus. [0038]
  • In some cases, two or more polypeptides can be made such that they are connected via a covalent bond. For example, two polypeptides can be made as a fusion protein such that they are connected by a peptide bond. Alternatively, a polypeptide can be made in a cell line that promotes the formation of disulfide bonds between, for example, two identical polypeptides. In this case, the conjugate would be a homodimer. It is noted that any polypeptide can be engineered to contain one or more cysteine residues such that the polypeptides form conjugates via cysteine bridges. For example, a polypeptide can be made to contain N- and C-terminal cysteine residues such that conjugates of varying size are formed intracellularly. [0039]
  • In addition, the interaction between biotin and avidin can be used to form conjugates. For example, polypeptides can be designed, or chemically treated, to contain biotin molecules at the C- and N-terminal ends. These biotin-containing polypeptide can be incubated with avidin molecules that are capable of simultaneously interacting with two or more biotin molecules. In this case, a single avidin molecule can link two biotin-containing polypeptides to form a conjugate. Further, chelating molecules that can simultaneously bind two or more ions (e.g., Ni[0040] ++, Cu++, Co++, and Zn++) can be used to form conjugates. For example, a copper chelating molecule that can interact with two copper ions can be used to link two polypeptides containing a polyhistidine sequence. In this case, a single copper ion can interact with each polyhistidine sequence while a single copper chelating molecule links the two polypeptides to form a conjugate. It is noted that immunostimulating complexes (iscoms) can be used to form conjugates. For example, an iscom can be designed to contain copper ions such that polypeptides containing a polyhistidine sequence can be conjugated.
  • Typically, a nucleic acid molecule is constructed such that a particular polypeptide is expressed. For example, a nucleic acid molecule can be constructed to encode a polypeptide having three similar amino acid segments as well as a polyhistidine sequence at its C-terminus. Once constructed, the nucleic acid molecule can be introduced into a host cell such that the polypeptide is produced. Any host cell can be used including, without limitation, prokaryotic cells (e.g., bacteria) and eukaryotic cells (e.g., human cells). Once produced, the polypeptide can be purified and used to make the desired vaccine conjugate. [0041]
  • The term “nucleic acid” as used herein encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. The nucleic acid can be double-stranded or single-stranded. Where single-stranded, the nucleic acid can be the sense strand or the antisense strand. In addition, nucleic acid can be circular or linear. [0042]
  • Nucleic acid can be obtained using common molecular cloning or chemical nucleic acid synthesis procedures and techniques, including PCR. PCR refers to a procedure or technique in which target nucleic acid is amplified in a manner similar to that described in U.S. Pat. No. 4,683,195, and subsequent modifications of the procedure described therein. Generally, sequence information from the ends of the region of interest or beyond are used to design oligonucleotide primers that are identical or similar in sequence to opposite strands of a potential template to be amplified. Using PCR, a nucleic acid sequence can be amplified from RNA or DNA. For example, a nucleic acid sequence can be isolated by PCR amplification from total cellular RNA, total genomic DNA, and cDNA as well as from bacteriophage sequences, plasmid sequences, viral sequences, and the like. When using RNA as a source of template, reverse transcriptase can be used to synthesize complimentary DNA strands. [0043]
  • Any method can be used to introduce, nucleic acid into a cell. In fact, many methods for introducing nucleic acid into cells, whether in vivo or in vitro, are well known to those skilled in the art. For example, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and viral-mediated nucleic acid transfer are common methods for introducing nucleic acid into cells. In addition, naked DNA can be delivered directly to cells in vivo as describe elsewhere (U.S. Pat. Nos. 5,580,859 and 5,589,466 including continuations thereof). Further, nucleic acid can be introduced into cells by generating transgenic animals. It is noted that transgenic animals such as rabbits, goats, sheep, and cows can be engineered such that large amounts of a polypeptide are secreted into their milk. [0044]
  • Transgenic animals can be aquatic animals (such as fish, sharks, dolphin, and the like), farm animals (such as pigs, goats, sheep, cows, horses, rabbits, and the like), rodents (such as rats, guinea pigs, and mice), non-human primates (such as baboon, monkeys, and chimpanzees), and domestic animals (such as dogs and cats). Several techniques known in the art can be used to introduce nucleic acid into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., [0045] Proc. Natl Acad. Sci., USA, 82:6148-6152 (1985)); gene transfection into embryonic stem cells (Gossler A et al., Proc Natl Acad Sci USA 83:9065-9069 (1986)); gene targeting into embryonic stem cells (Thompson et al., Cell, 56:313-321 (1989)); nuclear transfer of somatic nuclei (Schnieke AE et al., Science 278:2130-2133 (1997)); and electroporation of embryos.
  • For a review of techniques that can be used to generate and assess transgenic animals, skilled artisans can consult Gordon (Intl. Rev. Cytol., 115:171-229 (1989)), and may obtain additional guidance from, for example: Hogan et al., “Manipulating the Mouse Embryo” Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1986); Krimpenfort et al., [0046] Bio/Technology, 9:844-847 (199 1); Palmiter et al., Cell, 41:343-345 (1985); Kraemer et al., “Genetic Manipulation of the Early Mammalian Embryo” Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1985); Hammer et al., Nature, 315:680-683 (1985); Purscel et al., Science, 244:1281-1288 (1986); Wagner et al., U.S. Pat. No. 5,175,385; and Krimpenfort et al., U.S. Pat. No. 5,175,384.
  • In addition, a nucleic acid that encodes a polypeptide can be maintained within a cell in any form. For example, nucleic acid can be integrated into the genome of a cell or maintained in an episomal state. In other words, a cell can be a stable or transient transformant. [0047]
  • Further, any method can be used to direct the expression of a particular polypeptide. Such methods include, without limitation, constructing a nucleic acid such that a regulatory element promotes the expression of a nucleic acid sequence that encodes a polypeptide. Typically, regulatory elements are DNA sequences that regulate the expression of other DNA sequences at the level of transcription. Thus, regulatory elements include, without limitation, promoters, enhancers, and the like. [0048]
  • In one embodiment, a conjugate to vaccinate rats can be designed to contain polypeptides having an N-terminal polyhistidine sequence followed by an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH4 domain, and a C-terminal polyhistidine sequence. Alternatively, the first opossum IgE CH2 domain can be followed by three rat IgE CH3 domains as opposed to only one rat IgE CH3 domain. In either case, two polypeptides can be connected via disulfide bonds such that dimers are formed. It is noted that affinity chromatography can be used to purify polypeptides containing a polyhistidine sequence. In addition, an anti-polyhistidine antibody can be used as a linking molecule to connect any number of single polypeptides or dimers through the N-terminal and C-terminal polyhistidine sequences. For example, three dimers can be linked sequentially via two anti-polyhistidine antibodies (i.e., dimer one connected to dimer two by antibody one, and dimer two connected to dimer three by antibody two). It is noted that mixing polypeptides with a linking molecule can result in a vaccine that contains vaccine conjugates with various sizes as well as various combinations of polypeptides. For example, a vaccine can contain a substantial amount of vaccine conjugates having less than four polypeptides with few having greater than four polypeptides. It is also noted that the general configuration of the polypeptides within a vaccine conjugate can be adapted to vaccinate mammals other than rats. For example, the rat IgE domains can be replaced with human IgE domains to vaccinate humans. [0049]
  • 2. Vaccine Conjugates and Cytokines [0050]
  • The invention provides vaccine conjugates that contain a polypeptide having a cytokine activity such that a potent immune response is induced against another polypeptide within the conjugate. Such immune responses can be more potent than the responses induced by a conjugate lacking a polypeptide having a cytokine activity. Although not limited to any particular mode of action, a vaccine conjugate containing polypeptide X and a polypeptide having a cytokine activity presumably concentrates cytokine activity to the localized area containing polypeptide X. Thus a vaccine conjugate containing a polypeptide having cytokine activity can stimulate cells that participate in generating a specific immune response against other polypeptides within a vaccine conjugate. [0051]
  • A polypeptide having cytokine activity can have any type of cytokine activity. For example, a polypeptide can have interferon-α, interferon-β, interferon-γ, TNF-α, IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, or granulocyte-macrophage colony stimulating factor (GM-CSF) activity. It is important to note that a polypeptide having cytokine activity can be a polypeptide that is either naturally occurring or non-naturally occurring. A naturally occurring polypeptide is any polypeptide having an amino acid sequence as found in nature, including wild-type and polymorphic polypeptides. Such naturally occurring polypeptides can be obtained from any species including, without limitation, human, chimpanzee, baboon, rat, or mouse. For example, human interferon-α can be used in a vaccine conjugate. A non-naturally occurring polypeptide is any polypeptide having an amino acid sequence that is not found in nature. Thus, a non-naturally occurring polypeptide can be a mutated version of a naturally occurring polypeptide, or an engineered polypeptide. For example, a non-naturally occurring polypeptide having interferon-α activity can be a mutated version of a naturally occurring polypeptide having interferon-α activity that retains at least some interferon-α activity. A polypeptide can be mutated by, for example, sequence additions, deletions, and/or substitutions using standard methods such as site-directed mutagenesis of the corresponding nucleic acid coding sequence. [0052]
  • A conjugate can contain any number of polypeptides having cytokine activity. For example, a conjugate can contain two polypeptides having cytokine activity. In addition, a conjugate can contain polypeptides having different cytokine activities. For example, a conjugate can contain one polypeptide having interferon-α activity and another having GM-CSF activity. It is noted that polypeptides having cytokine activity can be obtained using any method. For example, a polypeptide having cytokine activity can be designed to contain a polyhistidine sequence such that affinity chromatography can be used to purify the polypeptide. In addition, any method can be used to form a conjugate. For example, a polypeptide having cytokine activity can be designed to contain a linker site such that a linking molecule can link that polypeptide to another polypeptide such as any of the polypeptides described herein. [0053]
  • In one embodiment, a conjugate to vaccinate rats can be designed to contain polypeptides having cytokine activity as well as polypeptides having an N-terminal polyhistidine sequence followed by an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH2 domain, a rat IgE CH3 domain, an opossum IgE CH4 domain, and a C-terminal polyhistidine sequence. In this case, the polypeptides having cytokine activity can contain an N-terminal polyhistidine sequence such that affinity chromatography can be used for purification. In addition, an anti-polyhistidine antibody can be used as a linking molecule to connect any number of polypeptides via the polyhistidine sequences. For example, a conjugate can contain an interferon-α polypeptide followed by three polypeptides containing IgE domains followed be an interferon-β polypeptide with each connection being via an anti-polyhistidine antibody. It is noted that mixing polypeptides with a linking molecule can result in a vaccine that contains vaccine conjugates with various sizes and various combinations of polypeptides. For example, a vaccine can contain a substantial amount of vaccine conjugates having polypeptides with interferon-α activity with few having both polypeptides with interferon-α activity and polypeptides with interferon-β activity. It is also noted that the general configuration of the polypeptides within a vaccine conjugate can be adapted to vaccinate mammals other than rats. For example, the rat IgE domains can be replaced with human IgE domains to vaccinate humans. [0054]
  • 3. Immunogenic Polypeptides and IgE Vaccines [0055]
  • For a successful IgE vaccination, it is essential to obtain a strong immune response that reacts predominantly with native IgE molecules (e.g., IgE surface epitopes). This is required in order to achieve efficient competition with the IgE receptor for free IgE, as the interaction between an IgE antibody and its specific IgE receptor is very strong (2.6×10[0056] −10; Froese A, CRC Crit. Rev. Immunol. 1:79-132 (1980)). As described herein, high levels of antibodies having specificity for self IgE antibodies were produced in rat strains by administering an immunogenic polypeptide. Several different rat strains were used including low, medium, and high IgE responders.
  • An immunogenic polypeptide, as described herein, is a polypeptide that effectively induces an immune response in a mammal. For example, an immunogenic polypeptide can be a polypeptide that effectively induces an anti-self IgE response in a mammal. Typically, immunogenic polypeptides contain at least one amino acid sequence (e.g., a single amino acid substitution) that would be considered non-self to a particular mammal. For example, immunogenic polypeptides that induce anti-self IgE responses can contain two components: a self IgE portion and a non-self IgE portion. The self IgE portion can be responsible for conferring the specificity of the anti-self IgE response and the non-self IgE portion can serve to promote and stabilize the immunogenic polypeptide such that the specific anti-self IgE response is induced. Typically, the self IgE portion of the immunogenic polypeptide is a portion of an IgE antibody that either directly interacts with an IgE receptor or indirectly influences the interaction of an IgE antibody with an IgE receptor. [0057]
  • Briefly, the binding site for human IgE to the high affinity IgE receptor on mast cells and basophils is not located at the junction between the CH2 and CH3 domains of IgE as previously suggested, but instead is located in the N-terminal region of the CH3 domain. This region is, due to folding, located in the junction between the CH3 and CH4 domains of the native polypeptide. Thus, use of the entire CH2-CH3 domain as a self IgE portion may potentially induce an anti-self IgE response with antibodies interacting with self IgE antibodies already bound to the surface of mast cells such that anaphylactic reactions occur. To reduce the risk of inducing an anaphylactic response, the self IgE portion of an immunogenic polypeptide can be the entire CH3 domain without the CH2 domain. Alternatively, the self IgE portion can be the N-terminal region of the CH3 domain. For example, when vaccinating a rat, the self IgE portion can be the N-terminal half of the rat CH3 domain in a context of a non-self IgE portion containing the entire CH2 domain of opossum IgE, the C-terminal half of the CH domain of opossum IgE, and the entire CH4 domain of opossum IgE. Such an immunogenic polypeptide can be designated ORO-trunc (FIG. 2). [0058]
  • Typically, the non-self IgE portion of an immunogenic polypeptide stabilizes a functional conformation of the self IgE portion. For example, if the self IgE portion is a CH3 domain, then the non-self IgE portion could be a CH2 domain, a CH4 domain, or a CH2 and CH4 domain with the self CH3 domain being between the CH2 and CH4 domains. Specifically, when vaccinating a rat, the self IgE portion can be the rat CH3 domain in a context of a non-self IgE portion from, for example, opossum. In this case, the rat CH3 domain can be located between the opossum CH2 and CH4 domains. Such an immunogenic polypeptide can be designated ORO (FIG. 2). Likewise, when vaccinating a mouse, the self IgE portion can be the mouse CH3 domain in a context of a non-self IgE portion from, for example, opossum. Such an immunogenic polypeptide can be designated OMO (FIG. 2). [0059]
  • Immunogenic polypeptides of the invention can be produced using a eukaryotic expression system, such as a mammalian cell expression system. In such cases, the immunogenic polypeptide is soluble, properly folded, and properly modified such that an anti-self IgE response is induced upon administration to a mammal. For example, immunogenic polypeptides having one or more eukaryotic post-translational modifications can produce an anti-self IgE response that is significantly higher than similar polypeptides lacking eukaryotic post-translational modification (e.g., a bacterially produced polypeptide). Eukaryotic post-translational modifications include, without limitation, glycosylation, acylation, limited proteolysis, phosphorylation, and isoprenylation. Further, soluble, properly folded, and properly modified immunogenic polypeptides can induce a strong anti-self IgE response in mammals with high concentrations of plasma IgE, so called high IgE responders. Bacterially produced polypeptides, however, are unable to produce such a strong anti-self IgE response in high IgE responders. Thus, immunogenic polypeptides having high solubility, proper folding, and proper modification can be obtained and used as described herein to induce effective anti-self IgE responses in mammals. Moreover, the immunogenic polypeptides described herein can be used to treat mammals, including humans, that have high serum concentrations of IgE. It is noted that a high percentage of the severely allergic patients in the human population belong to this category of patients. [0060]
  • The IgE CH3 domain, or a portion of an IgE CH3 domain, derived from an organism to be vaccinated such as human can be inserted into the structural context of a distantly related IgE molecule such as an IgE molecule from a non-placental mammal (e.g., opossum, platypus, koala, kangaroo, wallaby, and wombat). IgE antibodies from the grey short tailed opossum, a marsupial, exhibit about 25 percent sequence identity with human, rat, pig, and dog IgE antibodies. Thus, regions of the opossum IgE antibody can be used as the non-self IgE portion of an immunogenic polypeptide such that a potent anti-self IgE response is induced in a human, rat, pig, or dog. [0061]
  • A nucleic acid molecule for expressing an immunogenic polypeptide can be produced by splicing a first nucleic acid that encodes a portion of an IgE antibody from an organism to be vaccinated into a second nucleic acid that encodes a portion of an IgE antibody from a mammal distantly related to the organism to be vaccinated. For example, a nucleic acid molecule encoding an immunogenic polypeptide containing the CH3 domain of rat, human, pig, or dog IgE can be spliced into a nucleic acid containing the CH2 and CH4 domains of opossum IgE. Such chimeric nucleic acid molecules can be constructed using common molecular cloning techniques. In general, constructing nucleic acid such that the CH3 domain of an IgE antibody from one organism is positioned between the CH2 and CH4 domains of an IgE antibody from another organism results in a nucleic acid molecule that encodes a chimeric IgE molecule that has the CH3 domain in a structural context very similar to its native position within native IgE antibodies. [0062]
  • When vaccinating rat, human, dog, or pig, the opossum CH2 and CH4 domains can serve as the non-self IgE portion of the immunogenic polypeptide, since there is about 30 percent amino acid identity between opossum CH2 and CH4 domains and the corresponding domains of rat, human, dog, and pig IgE (FIG. 1). Such immunogenic polypeptides can be produced in a mammalian host. In addition, the resulting immunogenic polypeptides can be secreted from the mammalian producer cells in a properly folded and properly glycosylated form. For example, analysis, in the Biacore system. with monoclonal antibodies directed against the CH3 domain of human IgE revealed that these monoclonal antibodies can bind strongly to immunogenic polypeptides of the invention, indicating that the entire CH3 domain can be properly folded. [0063]
  • It is important to note that immunogenic polypeptides described herein can be such that deleterious side-effects are not exhibited, even in mammals that have highly elevated IgE titres prior to vaccination. In addition, vaccination with an immunogenic polypeptide as described herein can induce an anti-self IgE response that is directed against the entire free pool of IgE. Such a response is not limited to a specific allergen. Thus, these methods and materials can be used to treat human allergies having a large variety of different atopic allergies. [0064]
  • 4. Additional Components and Modes of Administration [0065]
  • The vaccines, vaccine conjugates, and immunogenic polypeptides described herein can be administered alone or in combination with other components. For example, a vaccine conjugate can contain a blocking molecule that inhibits the interaction between an antibody (e.g., an IgG antibody) and an Fc-gamma receptor II (e.g., CD32). Such blocking molecules (i.e., Fc-gamma receptor II blocking molecules) can include, without limitation, anti-CD32 antibodies. Anti-CD32 antibodies can be obtained using common antibody production and screening techniques. It is noted that Fc-gamma receptor II blocking molecules can be used in combination with any immunogenic polypeptide such that the immune response against the immunogenic polypeptide is enhanced. For example, a mixture containing an anti-CD32 antibody and an immunogenic polypeptide either conjugated or not can be administered to a mammal to induce a potent immune response against the immunogenic polypeptide. [0066]
  • To vaccinate a mammal, an effective amount of any vaccine, vaccine conjugate, or immunogenic polypeptide described herein can be administered to a host. An effective amount refers to any amount that induces a desired immune response while not inducing significant toxicity to the host. Such an amount can be determined by assessing a host's immune response after administration of a fixed amount of a particular material (e.g., immunization polypeptide). In addition, the level of toxicity, if any, can be determined by assessing a host's clinical symptoms before and after administering a fixed amount of a particular material. It is noted that the effective amount of a particular material administered to a host can be adjusted according to desired outcomes as well as the host's response and level of toxicity. Significant toxicity can vary for each particular host and depends on multiple factors including, without limitation, the host's disease state, age, and tolerance to pain. [0067]
  • In addition, any of the materials described herein can be administered to any part of the host's body including, without limitation, the joints, blood stream, lungs, intestines, muscle tissues, skin, and peritoneal cavity. Thus, a vaccine conjugate can be administered by intravenous, intraperitoneal, intramuscular, subcutaneous, intrathecal, and intradermal injection, by oral administration, by inhalation, or by gradual perfusion over time. For example, an aerosol preparation containing an immunogenic polypeptide can be given to a host by inhalation. It is noted that the duration of vaccination with any of the materials described herein can be any length of time from as short as one day to as long as a lifetime (e.g., many years). For example, an immunogenic polypeptide can be administered once a year over a period of ten years. It is also noted that the frequency of treatment can be variable. For example, an immunogenic polypeptide can be administered once (or twice, three times, etc.) daily, weekly, monthly, or yearly. [0068]
  • Preparations for administration can include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents include, without limitation, propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters. Aqueous carriers include, without limitation, water as well as alcohol, saline, and buffered solutions. Preservatives, flavorings, and other additives such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases, and the like may also be present. It will be appreciated that any material described herein that is to be administered to a mammal can contain one or more commonly known pharmaceutically acceptable carriers. [0069]
  • Any method can be used to determine if a particular immune response is induced. For example, antibody responses against particular antigens can be determined using immunological assays (e.g., ELISA). In addition, clinical methods that can assess the degree of a particular disease state can be used to determine if a desired immune response is induced. [0070]
  • The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. [0071]
    • EXAMPLES Example 1 IMMUNOGENIC POLYPEPTIDES
  • Nucleic acid molecules were constructed to encode immunogenic polypeptides containing both self and non-self IgE portions. These nucleic acid molecules were then used to synthesize soluble immunogenic polypeptides in mammalian cells. Such immunogenic polypeptides effectively induced a polyclonal anti-self IgE response upon administration to a mammal. In addition, the immunogenic polypeptides appear to be folded and glycosylated in a manner that enabled the immunogenic polypeptides to produce a strong and specific anti-self IgE response that was more potent than bacterially produced polypeptides lacking the non-self IgE portion. Thus, the immunogenic polypeptides described herein contain a majority of the surface epitopes in the same conformation as in native plasma IgE. Moreover, immunogenic polypeptides containing a self IgE portion limited to either the entire CH3 domain or a fragment of the CH3 domain (e.g., N-terminal region of CH3) reduced the potential of producing anaphylactic antibodies within a mammal. [0072]
    • Example 2 PRODUCTION AMD PURIFICATION OF AN IMMUNOGENIC POLYPEPTIDES
  • A ˜330 base pair PCR fragment encoding the CH3 domain of rat IgE (Hellman L et al., [0073] Nucleic Acids Res.10:6041-6049 (1982)) was fused with two similar sized fragments encoding the CH2 and CH4 domains of opossum IgE (Aveskogh M and Hellman L, Eur. J Immunol., 28:2738-2750 (1998)) by ligation into a modified version of the pCEP4 expression vector, pCEP-Pu2 (Margolskee R F et al., Mol. Cell Biol. 8:2837-2847 (1988)). This vector contains the CMV promoter-enhancer, located directly 5′ of the coding region of interest and allows high levels of expression in mammalian cells. This vector also contains the coding regions for puromycin resistance and the EBV EBNA1 gene. The EBNA1 gene confers maintenance of stable replicating-episomal copies of the vector in human or canine cell lines.
  • The nucleic acid molecule containing the opossum IgE CH2, rat IgE CH3, and opossum IgE CH4 nucleic acid sequences also contained nucleic acid sequences that encode a signal sequence and six histidine residues at the N-terminal region. The region containing the signal sequence and six histidine residues facilitates secretion of the encoded polypeptide from producer cells and enables polypeptide purification with Ni[0074] ++-chelating columns. Following transfection of the expression vector into human 293 cells, the opossum CH2-IgE/rat CH3-IgE/opossum CH4-IgE (ORO) immunogenic polypeptide was purified from 293 cell conditioned media on a nickel-chelating column to about 100 percent purity. Following elution of the ORO immunogenic polypeptide with a solution containing 20 mM Tris (pH 8.0), 0.1 M NaCl, and 100 mM imidazole, the eluate was dialyzed against PBS (pH 7.5) overnight at 4° C. The ORO immunogenic polypeptide was then concentrated to about 2 mg/mL using an Amicon concentrator. An aliquot of this preparation containing the ORO immunogenic polypeptide was separated on SDS-PAGE and found to be about 100 percent pure. This purified ORO immunogenic polypeptide preparation was used as the active component of an anti-self IgE vaccine for treating rats.
    • Example 3 SENSITIZATION PROCEDURE
  • Each rat was sensitized to ovalbumin as follows. Ten (10) μg of ovalbumin in PBS was administered to each rat intraperitoneally. Three weeks after this initial intraperitoneal injection of ovalbumin, the rats received weekly intraperitoneal injections of 1 μg of ovalbumin for four weeks. During this four week period, the rats became sensitized to ovalbumin obtaining a total IgE and ovalbumin-specific IgE response that was high and persistent. After this four week-period, the rats started a vaccination program. During the entire vaccination program, intraperitoneal injections of ovalbumin continued as follows. During the first two weeks of vaccination, the rats received intraperitoneal injections of 1 μg of ovalbumin weekly. After the first two weeks of vaccination, the rats received intraperitoneal injections of 1 μg of ovalbumin every other week. [0075]
    • Example 4 ELISA MEASUREMENT OF AN ANTI-SELF IgE RESPONSE
  • Thirty-six rats (twelve Lewis rats, twelve Louvain rats, and twelve Brown Norway rats) were divided into two equally sized groups and injected intraperitoneally with either the ORO immunogenic polypeptide or BSA as negative control. The BSA negative control was used at the same polypeptide concentration as that of the ORO immunogenic polypeptide. In this study, each rat received intraperitoneal injections of about 250 μg of antigen (either the ORO immunogenic polypeptide or BSA) dispersed in 0.2 mL of a 50:50 solution of Freund's complete adjuvant and PBS. Three weeks later, the rats were given a booster injection containing about 100 μg of antigen dispersed in 0.1 mL of a 50:50 solution of Freund's incomplete adjuvant and PBS. Six weeks later, the rats were given an additional booster identical to the first booster. One week after this third immunization, blood samples were taken and measured in an ELISA as follows. [0076]
  • The level of IgG anti-IgE antibodies directed against self rat IgE was measured by an ELISA. Native rat IgE was used at a concentration of 5 μg/mL for coating the ELISA plates. Successive 1/5 dilutions of serum from each of the individual rats were tested by color reaction in the ELISA. The presence of rat IgG antibodies having specificity for rat IgE antibodies was determined using two biotinylated mouse monoclonal antibodies, one with specificity for rat IgG2a/b and one for rat IgG1. Alkaline phosphatase coupled strepavidin was used to detect these biotinylated mouse monoclonal antibodies. [0077]
    • Example 5 INDUCTION OF AN ANTI-SELF IgE RESPONSE IN A MAMMAL
  • The in vivo effect of the ORO immunogenic polypeptide as an IgE vaccine was investigated using three different strains of rats (Lewis, Louvain, and Brown Norway). Lewis rats are low IgE responders, Louvain rats are medium IgE responders, and Brown Norway rats are high IgE responders. After sensitization to ovalbumin, each rat was vaccinated with either the ORO immunogenic polypeptide or BSA as described in Example 3. After collecting blood samples, the sera was diluted in steps of five as indicated (FIG. 3). Purified monoclonal rat IgE (IR 162) was used to coat the ELISA plates (5 μg/mL) and two biotinylated mouse monoclonal antibodies were used to detect rat IgG anti-IgE antibodies. Following the second booster dose, high anti-IgE titres were detected in the low, medium, and high IgE responding rats that received the vaccine containing the ORO immunogenic polypeptide. Anti-IgE titers were not detected in rats treated with the BSA control. Thus, the ORO immunogenic polypeptide was capable of inducing an anti-self IgE response in rats that contained low, medium, and high amounts of IgE antibodies. [0078]
  • A difference in anti-self IgE levels between the various strains was observed. The low responder strain, Lewis, showed very high anti-self IgE titres. The sera could be diluted more than 3000 times before a significant decrease in OD values upon ELISA measurements was detected (FIG. 3). For the high responder strain, Brown Norway, however, the OD values started to drop for three out of six animals at a dilution of 25 times or more (FIG. 3). [0079]
  • In another experiment, Wistar rats were used. Wistar rats are medium IgE responders. The anti-self IgE response produced by the Wistar rats was similar to the response observed in the Lewis rats. [0080]
    • Example 6 ANALYSIS OF CROSS REACTIVITY
  • The cross reactivity between rat antibodies directed against an opossum IgE CH2 or CH4 domain with the corresponding domain of rat IgE antibodies was evaluated. This potential cross reactivity could result from a low primary amino acid sequence homology or a close structural similarity between the CH2 and CH4 domains of opossum IgE and rat IgE. The induction of an anti-rat IgE response having specificity for the rat CH2 or CH4 domains could lead to mast cell activation. [0081]
  • A recombinant polypeptide (OOO) containing the opossum CH2-CH3-CH4 domains was injected into the Wistar strain. After a second booster injection, sera from these rats were collected and tested for the presence of antibodies having specificity for rat IgE. No anti-rat IgE antibodies were detected in the rats treated with the OOO polypeptide (FIG. 4). In addition, Wistar rats treated with the ORO immunogenic polypeptide exhibited an anti-self IgE response similar to that observed in Lewis rats. Further, Wistar rats treated with a recombinant polypeptide (PPP) containing platypus CH2-CH3-CH4 domains did not produce an anti-rat IgE response. Thus, the CH2, CH3, and CH4 domains of opossum and platypus IgE antibodies do not generate, upon administration to rats, rat antibodies having specificity for rat IgE antibodies. [0082]
  • The interaction between the rat antibodies induced by the ORO immunogenic polypeptide (rat IgG anti-self IgE antibodies) and human IgE antibodies was examined. In a few cases, minor cross reactivity was observed. This minor cross reactivity detected in a few rats was most likely caused by the interaction between rat IgG anti-rat CH3 IgE antibodies and the CH3 domain of human IgE. Since the CH3 domains of rat and human IgE are much more closely related than human and opossum or platypus IgE, vaccines containing opossum or platypus components can be considered highly safe, presenting minimal risk for the generation of cross linking antibodies. [0083]
    • Example 7 POLYPEPTIDES FOR VACCINE CONJUGATES
  • The nucleic acid construct encoding the ORO immunogenic polypeptide described in Example 2 was used to produce two polypeptides each having several identical self epitopes. One polypeptide contained two identical clusters of self epitopes (the entire rat CH3 domain), while the other polypeptide contained four such clusters. First, nucleic acid encoding six histidine residues was added to the C-terminal end of the opossum CH4 domain by including a nucleotide sequence for six histidine residues in the 3′ PCR primer. Thus, each polypeptide contained a polyhistidine sequence at both the N- and C-terminal ends so that conjugates can be formed. Second, a nucleic acid fragment encoding the opossum CH2 and the rat CH3 domains of the original construct was obtained by PCR amplification. This fragment was subsequently ligated into the construct encoding the ORO immunogenic polypeptide. The resulting construct encoded a polypeptide designated ORORO. This ORORO polypeptide contains two rat CH3 domains, two opossum CH2 domains, and one opossum CH4 domain in the following order opossum CH2, rat CH3, opossum CH2, rat CH3, and opossum CH4. Thus, this polypeptide has two identical CH3 domains, each with multiple self epitopes. [0084]
  • The nucleic acid construct encoding ORORO was used as starting material to produce the second immunogenic polypeptide. This polypeptide contains two additional rat CH3 domains that were added to a position 3′ of the first rat CH3 domain in the ORORO polypeptide. The resulting polypeptide has a polyhistidine tag followed by an opossum CH2 domain, three identical rat CH3 domains, one opossum CH2 domain, one rat CH3 domain, an opossum CH4 domain, and a C-terminal polyhistidine tag (6his-ORRRORO-6his). [0085]
  • Each recombinant polypeptide was produced in the pCEP4 based vector system. In addition, the polypeptides were purified using Ni[0086] ++chelating columns according to the method described in Example 2. Similar vaccine constructs are produced using dog or human IgE CH3 domain instead of the rat IgE CH3 domain.
    • Example 8 VACCINE CONJUGATES
  • To determine a favorable combination of polypeptide to monoclonal antibody, the purified polypeptides of Example 7 are mixed with a monoclonal anti-polyhistidine antibody in various combinations ranging from a 1/1 to a 10/1 ratio (polypeptide to monoclonal antibody ratio). This mixture results in the generation of long multimeric conjugates with a large number of identical self epitopes in tandem. The biological activity of the various combinations is assessed in rats as described herein. The non-conjugated ORO immunogenic polypeptide is used as a reference to assess immune responses. [0087]
    • Example 9 POLYPEPTIDES HAVING CYTOKINE ACTIVITY
  • PCR primers are designed so that cDNAs encoding rat, dog, and human cytokines (e.g., interferon-α, interferon-γ, and GM-CSF) can be isolated from total spleen mRNA. The nucleotide sequence encoding six histidine residues is introduced into each 5′ PCR primer so that the cytokines can be purified via affinity chromatography and can be non-covalently conjugated to the polypeptides described herein via an anti-polyhistidine antibody. The recombinant cytokines are produced using any one of the following three expression systems: bacteria, yeast (e.g., [0088] Pichia pastoris), and mammalian cells (e.g., 293-EBNA cells using a pCEP-4 based expression system).
    • Example 10 VACCINE CONJUGATES HAVING A POLYPEPTIDE WITH CYTOKINE ACTIVITY
  • Cytokines produced according to Example 9 are used to make vaccine conjugates. A mixture of three different cytokines (e.g., mouse interferon-α, rat interferon-γ and rat GM-CSF) is produced and tested in combination with the ORORO polypeptide and an anti-polyhistidine antibody. [0089]
  • Initially, a mixture of 1/10 ratio (cytokine to immunogenic polypeptide ratio) is tested. With three cytokines, this ratio results in a mixture of 30% cytokine per molar basis and 70% immunogenic polypeptide. In addition, this mixture contains an anti-polyhistidine antibody at a 1/10 ratio (immunogenic polypeptide to monoclonal antibody ratio). A large number of ratio combinations is evaluated so that an optimal cytokine to immunogenic polypeptide ratio as well as an optimal monoclonal antibody to immunogenic polypeptide ratio is determined. In addition, polypeptides having cytokine activity from various species is assessed to determine the optimal combination for a particular species. [0090]
    • OTHER EMBODIMENTS
  • It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. [0091]
  • 1 11 1 331 PRT Artificial Sequence Synthetically generated proteins 1 Asp Asn Lys Thr Phe Ser Val Cys Ser Arg Asp Phe Thr Pro Pro Thr 1 5 10 15 Val Lys Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro 20 25 30 Thr Ile Gln Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile 35 40 45 Asn Ile Thr Trp Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Ser 50 55 60 Thr Ala Ser Thr Thr Gln Glu Gly Glu Leu Ala Ser Thr Gln Ser Glu 65 70 75 80 Leu Thr Leu Ser Gln Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys 85 90 95 Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys 100 105 110 Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser 115 120 125 Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val 130 135 140 Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg 145 150 155 160 Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln 165 170 175 Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg 180 185 190 Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His 195 200 205 Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg 210 215 220 Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser 225 230 235 240 Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu 245 250 255 Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala 260 265 270 Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe 275 280 285 Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp 290 295 300 Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr 305 310 315 320 Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys 325 330 2 340 PRT Artificial Sequence Synthetically generated proteins 2 Asp Leu Thr Ile Arg Ala Arg Pro Val Asn Ile Thr Lys Pro Thr Val 1 5 10 15 Asp Leu Leu His Ser Ser Cys Asp Pro Asn Ala Phe His Ser Thr Ile 20 25 30 Gln Leu Tyr Cys Phe Val Tyr Gly His Ile Gln Asn Asp Val Ser Ile 35 40 45 His Trp Leu Met Asp Asp Arg Lys Ile Tyr Glu Thr His Ala Gln Asn 50 55 60 Val Leu Ile Lys Glu Glu Gly Lys Leu Ala Ser Thr Tyr Ser Arg Leu 65 70 75 80 Asn Ile Thr Gln Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys 85 90 95 Val Thr Ser Gln Gly Glu Asn Tyr Trp Ala His Thr Arg Arg Cys Ser 100 105 110 Asp Asp Glu Pro Arg Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro 115 120 125 Leu Asp Leu Tyr Glu Asn Gly Thr Pro Lys Leu Thr Cys Leu Val Leu 130 135 140 Asp Leu Glu Ser Glu Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg 145 150 155 160 Lys Lys Ser Ile Gly Ser Ala Ser Gln Arg Ser Thr Lys His His Asn 165 170 175 Ala Thr Thr Ser Ile Thr Ser Ile Leu Pro Val Asp Ala Lys Asp Trp 180 185 190 Ile Glu Gly Glu Gly Tyr Gln Cys Arg Val Asp His Pro His Phe Pro 195 200 205 Lys Pro Ile Val Arg Ser Ile Thr Lys Ala Pro Gly Lys Arg Ser Ala 210 215 220 Pro Glu Val Tyr Val Phe Leu Pro Pro Glu Glu Glu Glu Lys Asp Lys 225 230 235 240 Arg Thr Leu Thr Cys Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser 245 250 255 Val Gln Trp Leu Gln Asp Ser Lys Leu Ile Pro Lys Ser Gln His Ser 260 265 270 Thr Thr Thr Pro Leu Lys Tyr Asn Gly Ser Asn Gln Arg Phe Phe Ile 275 280 285 Phe Ser Arg Leu Glu Val Thr Lys Ala Leu Trp Thr Gln Thr Lys Gln 290 295 300 Phe Thr Cys Arg Val Ile His Glu Ala Leu Arg Glu Pro Arg Lys Leu 305 310 315 320 Glu Arg Thr Ile Ser Lys Ser Leu Gly Asn Thr Ser Leu Arg Pro Ser 325 330 335 Gln Ala Ser Met 340 3 341 PRT Artificial Sequence Synthetically generated proteins 3 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ala Gln Lys Cys Ser Asp Thr Asp Pro Arg 115 120 125 Gly Ile Ser Ala Tyr Ile Leu Pro Pro Thr Pro Gln Asp Leu Phe Val 130 135 140 Lys Lys Val Pro Thr Ile Gly Cys Leu Ile Val Asp Leu Ala Ser Ala 145 150 155 160 Glu Asn Val Lys Val Thr Trp Ser Arg Glu Ser Gly Gly Pro Val Asn 165 170 175 Pro Ser Ser Leu Val Val Lys Glu Gln Tyr Asn Gly Thr Phe Thr Val 180 185 190 Thr Ser His Leu Pro Val Asn Thr Asp Asp Trp Ile Glu Gly Asp Thr 195 200 205 Tyr Thr Cys Arg Leu Glu Ser Pro Asp Met Pro Val Pro Leu Ile Arg 210 215 220 Thr Ile Ser Lys Ala Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr Met 225 230 235 240 Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr Cys 245 250 255 Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu Phe 260 265 270 Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro Gln 275 280 285 Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met Leu 290 295 300 Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg Val 305 310 315 320 Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu His 325 330 335 Tyr Ser Ala Gly Asn 340 4 341 PRT Artificial Sequence Synthetically generated proteins 4 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Arg Cys Ser Asp Asp Glu Pro Arg 115 120 125 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Glu 130 135 140 Asn Gly Thr Pro Lys Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu 145 150 155 160 Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg Lys Lys Ser Ile Gly 165 170 175 Ser Ala Ser Gln Arg Ser Thr Lys His His His Ala Thr Thr Ser Ile 180 185 190 Thr Ser Ile Leu Pro Val Asp Ala Lys Asp Trp Ile Glu Gly Glu Gly 195 200 205 Tyr Gln Cys Arg Val Asp His Pro His Phe Pro Lys Pro Ile Val Arg 210 215 220 Ser Ile Thr Lys Leu Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr Met 225 230 235 240 Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr Cys 245 250 255 Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu Pro 260 265 270 Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro Gln 275 280 285 Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met Leu 290 295 300 Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg Val 305 310 315 320 Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu His 325 330 335 Tyr Ser Ala Gly Asn 340 5 342 PRT Artificial Sequence Synthetically generated proteins 5 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Arg Cys Ser Asp Asp Glu Pro Arg 115 120 125 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Glu 130 135 140 Asn Gly Thr Pro Lys Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu 145 150 155 160 Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg Lys Lys Ser Ile Gly 165 170 175 Ser Ala Arg Ser Leu Val Val Lys Glu Gln Tyr Asn Gly Thr Phe Thr 180 185 190 Val Thr Ser His Leu Pro Val Asn Thr Asp Asp Trp Ile Glu Gly Asp 195 200 205 Thr Tyr Thr Cys Arg Leu Glu Ser Pro Asp Met Pro Tyr Pro Leu Ile 210 215 220 Arg Thr Ile Ser Lys Ala Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr 225 230 235 240 Met Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr 245 250 255 Cys Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu 260 265 270 Pro Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro 275 280 285 Gln Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met 290 295 300 Leu Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg 305 310 315 320 Val Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu 325 330 335 His Tyr Ser Ala Gly Asn 340 6 341 PRT Artificial Sequence Synthetically generated proteins 6 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Arg Cys Pro Asp His Glu Pro Arg 115 120 125 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Gln 130 135 140 Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser Glu 145 150 155 160 Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr Ser Val Asn 165 170 175 Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr Thr Ser Ile 180 185 190 Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu Gly Tyr Gly 195 200 205 Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro Ile Val Arg 210 215 220 Ser Ile Thr Lys Leu Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr Met 225 230 235 240 Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr Cys 245 250 255 Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu Pro 260 265 270 Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro Gln 275 280 285 Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met Leu 290 295 300 Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg Val 305 310 315 320 Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu His 325 330 335 Tyr Ser Ala Gly Asn 340 7 343 PRT Artificial Sequence Synthetically generated proteins 7 Glu Phe His His His His His His Thr Glu Val Tyr Ser Asp Ser Ser 1 5 10 15 Lys Asp Pro Ile Pro Pro Thr Val Lys Leu Leu His Ser Ser Cys Asp 20 25 30 Pro Arg Gly Asp Ser Gln Ala Ser Ile Glu Leu Leu Cys Leu Ile Thr 35 40 45 Gly Tyr Ser Pro Ala Gly Ile Gln Val Asp Trp Leu Val Asp Gly Gln 50 55 60 Lys Ala Glu Asn Leu Phe Pro Tyr Thr Ala Pro Pro Lys Arg Glu Gly 65 70 75 80 Asn Arg Ser Phe Ser Ser His Ser Glu Val Asn Ile Thr Gln Asp Gln 85 90 95 Trp Leu Ser Gly Lys Thr Phe Thr Cys Gln Val Thr His Leu Ala Asp 100 105 110 Lys Lys Thr Tyr Gln Asp Ser Ala Pro Lys Cys Ala Asp Ser Asp Pro 115 120 125 Arg Gly Ile Thr Val Phe Ile Thr Pro Pro Ser Pro Thr Asp Leu Tyr 130 135 140 Ile Ser Lys Thr Pro Lys Leu Thr Cys Leu Ile Ile Asp Leu Val Ser 145 150 155 160 Thr Glu Gly Met Glu Val Thr Trp Ser Arg Glu Ser Gly Thr Pro Leu 165 170 175 Ser Ala Glu Ser Phe Glu Glu Gln Lys Gln Phe Asn Gly Thr Met Ser 180 185 190 Phe Ile Ser Thr Val Pro Val Asn Ile Gln Asp Trp Asn Arg Gly Glu 195 200 205 Ser Tyr Thr Cys Pro Val Ala His Pro Asp Leu Pro Ser Pro Ile Ile 210 215 220 Lys Thr Val Thr Lys Leu Pro Gly Lys Pro Leu Ala Pro Glu Val Tyr 225 230 235 240 Ala Phe Pro Pro His Gln Ala Glu Val Ser His Gly Ala Ser Leu Ser 245 250 255 Leu Thr Cys Leu Ile Pro Gly Phe Tyr Pro Glu Asn Ile Ser Val Arg 260 265 270 Trp Leu Leu Asp Asn Lys Pro Leu Pro Thr Glu His Tyr Arg Thr Thr 275 280 285 Lys Pro Leu Lys Asp Gln Gly Pro Asp Pro Ala Tyr Phe Leu Tyr Ser 290 295 300 Pro Leu Ala Val Asn Lys Ser Thr Trp Glu Gln Gly Asn Val Tyr Thr 305 310 315 320 Cys Gln Val Val His Glu Ala Leu Pro Ser Arg Asn Thr Glu Arg Lys 325 330 335 Phe Gln His Thr Ser Gly Asn 340 8 342 PRT Artificial Sequence Synthetically generated proteins 8 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Lys Cys Ala Asp Ser Asn Pro Arg 115 120 125 Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile 130 135 140 Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser 145 150 155 160 Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val 165 170 175 Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr 180 185 190 Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu 195 200 205 Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met 210 215 220 Arg Ser Thr Thr Lys Leu Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr 225 230 235 240 Met Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr 245 250 255 Cys Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu 260 265 270 Phe Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro 275 280 285 Gln Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met 290 295 300 Leu Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg 305 310 315 320 Val Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu 325 330 335 His Tyr Ser Ala Gly Asn 340 9 341 PRT Artificial Sequence Synthetically generated proteins 9 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Arg Cys Ser Asp Asp Glu Pro Arg 115 120 125 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Glu 130 135 140 Asn Gly Thr Pro Lys Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu 145 150 155 160 Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg Lys Lys Ser Ile Gly 165 170 175 Ser Ala Ser Gln Arg Ser Thr Lys His His Asn Ala Thr Thr Ser Ile 180 185 190 Thr Ser Ile Leu Pro Val Asp Ala Lys Asp Trp Ile Glu Gly Glu Gly 195 200 205 Tyr Gln Cys Arg Val Asp His Pro His Phe Pro Lys Pro Ile Val Arg 210 215 220 Ser Ile Thr Lys Leu Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr Met 225 230 235 240 Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr Cys 245 250 255 Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu Phe 260 265 270 Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro Gln 275 280 285 Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met Leu 290 295 300 Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg Val 305 310 315 320 Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu His 325 330 335 Tyr Ser Ala Gly Asn 340 10 345 PRT Artificial Sequence Synthetically generated proteins 10 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Arg Cys Thr Ala Glu Ser Glu Pro 115 120 125 Arg Gly Val Ser Ala Tyr Leu Ser Pro Pro Thr Pro Leu Asp Leu Tyr 130 135 140 Val His Lys Ser Pro Lys Leu Thr Cys Leu Val Val Asp Leu Ala Ser 145 150 155 160 Ser Glu Asn Val Asn Leu Leu Trp Ser Arg Glu Asn Lys Gly Gly Val 165 170 175 Ile Leu Pro Pro Pro Gly Pro Pro Val Ile Lys Pro Gln Phe Asn Gly 180 185 190 Thr Phe Ser Ala Thr Ser Thr Leu Pro Val Asn Val Ser Asp Trp Ile 195 200 205 Glu Gly Glu Thr Tyr Tyr Cys Asn Val Thr His Pro Asp Leu Pro Lys 210 215 220 Pro Ile Leu Arg Ser Ile Ser Lys Leu Pro Gly Lys Arg Leu Ala Pro 225 230 235 240 Glu Val Tyr Met Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg 245 250 255 Thr Val Thr Cys Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val 260 265 270 Gln Trp Leu Phe Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr 275 280 285 Thr Arg Pro Gln Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr 290 295 300 Ser Arg Met Leu Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val 305 310 315 320 Thr Cys Arg Val Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu 325 330 335 Lys Ser Leu His Tyr Ser Ala Gly Asn 340 345 11 341 PRT Artificial Sequence Synthetically generated proteins 11 Glu Phe His His His His His His Thr Leu Ser Leu Pro Glu Ser Gly 1 5 10 15 Pro Val Thr Ile Ile Pro Pro Thr Val Lys Leu Phe His Ser Ser Cys 20 25 30 Asp Pro Arg Gly Asp Ala His Ser Thr Ile Gln Leu Leu Cys Leu Val 35 40 45 Ser Gly Phe Ser Pro Ala Lys Val His Val Thr Trp Leu Val Asp Gly 50 55 60 Gln Glu Ala Glu Asn Leu Phe Pro Tyr Thr Thr Arg Pro Lys Arg Glu 65 70 75 80 Gly Gly Gln Thr Phe Ser Leu Gln Ser Glu Val Asn Ile Thr Gln Gly 85 90 95 Gln Trp Met Ser Ser Asn Thr Tyr Thr Cys His Val Lys His Asn Gly 100 105 110 Ser Ile Phe Glu Asp Ser Ser Arg Lys Cys Ser Glu Ser Asp Pro Arg 115 120 125 Gly Val Thr Ser Tyr Leu Ser Pro Pro Ser Pro Leu Asp Leu Tyr Val 130 135 140 His Lys Ala Pro Lys Ile Thr Cys Leu Val Val Asp Leu Ala Thr Met 145 150 155 160 Glu Gly Met Asn Leu Thr Trp Tyr Arg Glu Ser Lys Glu Pro Val Asn 165 170 175 Pro Gly Pro Leu Asn Lys Lys Asp His Phe Asn Gly Thr Ile Thr Val 180 185 190 Thr Ser Thr Leu Pro Val Asn Thr Asn Asp Trp Ile Glu Gly Glu Thr 195 200 205 Tyr Tyr Cys Arg Val Thr His Pro His Leu Pro Lys Asp Ile Val Arg 210 215 220 Ser Ile Ala Lys Leu Pro Gly Lys Arg Leu Ala Pro Glu Val Tyr Met 225 230 235 240 Leu Pro Pro Ser Pro Glu Glu Thr Gly Thr Thr Arg Thr Val Thr Cys 245 250 255 Leu Ile Arg Gly Phe Tyr Pro Ser Glu Ile Ser Val Gln Trp Leu Phe 260 265 270 Asn Asn Glu Glu Asp His Thr Gly His His Thr Thr Thr Arg Pro Gln 275 280 285 Lys Asp His Gly Thr Asp Pro Ser Phe Phe Leu Tyr Ser Arg Met Leu 290 295 300 Val Asn Lys Ser Ile Trp Glu Lys Gly Asn Leu Val Thr Cys Arg Val 305 310 315 320 Val His Glu Ala Leu Pro Gly Ser Arg Thr Leu Glu Lys Ser Leu His 325 330 335 Tyr Ser Ala Gly Asn 340

Claims (24)

What is claimed is:
1. An immunogenic polypeptide, comprising a self IgE portion and a non-self IgE portion, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal.
2. The immunogenic polypeptide of claim 1, wherein said mammal is a human.
3. The immunogenic polypeptide of claim 1, wherein said self portion comprises at least a portion of a CH3 domain of IgE.
4. The immunogenic polypeptide of claim 1, wherein said polypeptide is capable of dimerizing to form a soluble immunogenic dimer effective to induce said anti-self IgE response in said mammal.
5. The immunogenic polypeptide of claim 1, wherein said non-self IgE portion comprises a first region and a second region, said self IgE portion being located between said first and second regions of said non-self IgE portion.
6. The immunogenic polypeptide of claim 5, wherein said first region comprises at least a portion of an IgE CH2 domain.
7. The immunogenic polypeptide of claim 5, wherein said second region comprises at least a portion of an IgE CH4 domain.
8. The immunogenic polypeptide of claim 1, wherein said non-self IgE portion comprises an IgE sequence present in a non-placental mammal.
9. The immunogenic polypeptide of claim 8, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.
10. The immunogenic polypeptide of claim 1, wherein said self IgE portion lacks the CH2 domain of an IgE antibody.
11. The immunogenic polypeptide of claim 1, wherein said anti-self IgE response is a polyclonal response.
12. A vaccine complex for vaccinating a mammal, said complex comprising a first and second polypeptide, wherein each of said first and second polypeptides contains at least two similar amino acid sequences at least five amino acid residues in length, wherein said first and second polypeptides are connected to form said complex, and wherein administration of said complex to said mammal induces an immune response against at least a portion of said first or second polypeptide.
13. The complex of claim 12, wherein said first or second polypeptide comprises an amino acid sequence expressed by said mammal.
14. The complex of claim 12, wherein said first and second polypeptides are identical.
15. The complex of claim 12, wherein the connection of said first and second polypeptides comprises a disulfide bond.
16. The complex of claim 12, wherein the connection of said first and second polypeptides comprises a non-covalent interaction.
17. The complex of claim 12, wherein said first or second polypeptide comprises a linker site.
18. The complex of claim 12, wherein said complex comprises a linking molecule.
19. The complex of claim 18, wherein said linking molecule connects said first and second polypeptide.
20. The complex of claim 12, wherein said complex comprises a third polypeptide, said third polypeptide having a cytokine activity.
21. The complex of claim 20, wherein said cytokine activity is an activity of a cytokine selected from the group consisting of interferon-α, interferon-β, interferon-γ, TNF-α, IL-1, IL-2, IL-4, IL-6, IL-12, IL-15, IL-18, and granulocyte-macrophage colony stimulating factor.
22. A vaccine complex for vaccinating a mammal, said complex comprising a first polypeptide connected to a second polypeptide, wherein said first polypeptide contains at least two similar amino acid sequences at least five amino acids in length, wherein said second polypeptide has a cytokine activity, and wherein administration of said complex to said mammal induces an immune response against at least a portion of said first polypeptide.
23. A vaccine complex for vaccinating a mammal, said complex comprising a first, second, and third polypeptide, wherein said first, second, and third polypeptides are connected to form said complex, wherein said first polypeptide has a first cytokine activity, wherein said second polypeptide has a second cytokine activity, and wherein administration of said complex to said mammal induces an immune response against at least a portion of said third polypeptide.
24. A vaccine complex for vaccinating a mammal, said complex comprising a first polypeptide connected to a second polypeptide, wherein said first polypeptide is a polypeptide having interferon-α or interferon-β activity, and wherein administration of said complex to said mammal induces an immune response against at least a portion of said second polypeptide.
US10/673,594 1998-11-02 2003-09-29 Enhanced vaccines Abandoned US20040076625A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/673,594 US20040076625A1 (en) 1998-11-02 2003-09-29 Enhanced vaccines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses
US10/673,594 US20040076625A1 (en) 1998-11-02 2003-09-29 Enhanced vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/401,636 Continuation US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses

Publications (1)

Publication Number Publication Date
US20040076625A1 true US20040076625A1 (en) 2004-04-22

Family

ID=26803871

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/401,636 Expired - Fee Related US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses
US10/176,664 Expired - Fee Related US7459158B2 (en) 1998-11-02 2002-06-19 Immunogenic polypeptides for inducing anti-self IgE responses
US10/673,594 Abandoned US20040076625A1 (en) 1998-11-02 2003-09-29 Enhanced vaccines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/401,636 Expired - Fee Related US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses
US10/176,664 Expired - Fee Related US7459158B2 (en) 1998-11-02 2002-06-19 Immunogenic polypeptides for inducing anti-self IgE responses

Country Status (18)

Country Link
US (3) US6913749B2 (en)
EP (1) EP1135158B1 (en)
JP (2) JP4205861B2 (en)
KR (1) KR100559918B1 (en)
AT (1) ATE314087T1 (en)
AU (1) AU771889B2 (en)
CA (1) CA2348756A1 (en)
DE (1) DE69929240T2 (en)
DK (1) DK1135158T3 (en)
ES (1) ES2255325T3 (en)
HK (1) HK1042844A1 (en)
HU (1) HUP0105392A3 (en)
IL (1) IL142582A0 (en)
NO (1) NO20012135L (en)
NZ (1) NZ511079A (en)
PL (1) PL348611A1 (en)
PT (1) PT1135158E (en)
WO (1) WO2000025722A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
US20110206659A1 (en) * 2008-05-23 2011-08-25 Dennis Penn Methods and treatment for allergies and inflammation associated with gastrointestinal diseases

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
WO2002020038A2 (en) * 2000-09-06 2002-03-14 Pharmexa A/S Method for down-regulating ige
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
BR0207399A (en) 2001-02-20 2004-10-26 Ortho Mcneil Pharm Inc Cell therapy method for tumor treatment
WO2002092773A2 (en) 2001-05-15 2002-11-21 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
JP2003047482A (en) * 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
WO2003096966A2 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
CA2497660A1 (en) * 2002-09-05 2004-03-18 Resistentia Pharmaceuticals Ab Allergy vaccines
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
WO2013191166A1 (en) * 2012-06-18 2013-12-27 日本全薬工業株式会社 IgE PEPTIDE VACCINE
WO2017143062A1 (en) 2016-02-16 2017-08-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483793A (en) * 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4782137A (en) * 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5196197A (en) * 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5334379A (en) * 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5420247A (en) * 1990-12-13 1995-05-30 Immunex Corporation Leukemia inhibitory factor receptors and fusion proteins
US5501855A (en) * 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5653980A (en) * 1991-09-26 1997-08-05 Hellman; Lars T. Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions
US5698201A (en) * 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5733553A (en) * 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
US5762931A (en) * 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5827668A (en) * 1990-05-25 1998-10-27 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US5945104A (en) * 1994-11-04 1999-08-31 Peptide Therapeutics Limited Peptides for anti-allergy treatment
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
US6034066A (en) * 1995-07-17 2000-03-07 Peptide Therapeutics Limited Cysteine protease inhibitors for use in treatment of IGE mediated allergic diseases
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20020141989A1 (en) * 1999-04-14 2002-10-03 Franz Kricek Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobulin E to its high affinity receptors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
ATE121299T1 (en) 1987-12-31 1995-05-15 Tanox Biosystems Inc ANTIGEN EPITOPES LOCATED EXCLUSIVELY ON IGE-BEARING B-LYMPHOCYTES.
JP3095168B2 (en) 1988-02-05 2000-10-03 エル． モリソン，シェリー Antibodies with domain-denaturing constants
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
ATE154637T1 (en) 1990-01-23 1997-07-15 Tanox Biosystems Inc EXTRACELLULAR PORTIONS OF HUMAN IGE IMMUNOGLOBULIN ANCHOR PEPTIDES AND SPECIFIC ANTIBODIES THEREFOR
EP0662085A1 (en) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
WO1994008601A1 (en) 1992-10-14 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
DK96493D0 (en) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps PROCEDURE FOR INDUCING ANTIBODY RESPONSE TO SELF-PROTEINS AND AUTOVACCINE PROCESSED BY THE PROCEDURE
FR2715304B1 (en) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Anti-allergic vaccine.
WO1995026365A1 (en) 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
AU4012095A (en) 1994-10-25 1996-05-15 United Biomedical Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (en) 1995-04-07 1996-12-17 Hoechst Japan Ltd Peptide and autoimmune disease-treating medicine comprising the same
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
KR100584051B1 (en) 1996-03-01 2006-05-30 노파르티스 아게 Peptide Immunogens for Vaccination against and Treatment of Allergy
AU730477B2 (en) 1996-08-05 2001-03-08 President And Fellows Of Harvard College MHC binding peptide oligomers and methods of use
HUP0001930A3 (en) 1997-04-15 2001-10-29 Pharmexa As Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
AU3291099A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Genetic vaccine vector engineering
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
HUP0103976A3 (en) 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
WO2000032227A2 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
CN1355846A (en) 1999-04-23 2002-06-26 法麦克萨有限公司 Method for down-regulating IL5 activity
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
WO2002020038A2 (en) 2000-09-06 2002-03-14 Pharmexa A/S Method for down-regulating ige
MXPA03011499A (en) 2001-06-15 2004-04-05 Tanox Inc Fce fusion proteins for treatment of allergy and asthma.

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) * 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) * 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) * 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (en) * 1986-01-30 1990-11-27 Cetus Corp
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5580859A (en) * 1989-03-21 1996-12-03 Vical Incorporated Delivery of exogenous DNA sequences in a mammal
US5589466A (en) * 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
US5334379A (en) * 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) * 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5827668A (en) * 1990-05-25 1998-10-27 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
US5196197A (en) * 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
US5420247A (en) * 1990-12-13 1995-05-30 Immunex Corporation Leukemia inhibitory factor receptors and fusion proteins
US5653980A (en) * 1991-09-26 1997-08-05 Hellman; Lars T. Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
US5762931A (en) * 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) * 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
US5945104A (en) * 1994-11-04 1999-08-31 Peptide Therapeutics Limited Peptides for anti-allergy treatment
US6034066A (en) * 1995-07-17 2000-03-07 Peptide Therapeutics Limited Cysteine protease inhibitors for use in treatment of IGE mediated allergic diseases
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US20020141989A1 (en) * 1999-04-14 2002-10-03 Franz Kricek Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobulin E to its high affinity receptors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
US20110206659A1 (en) * 2008-05-23 2011-08-25 Dennis Penn Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US9649303B2 (en) 2008-05-23 2017-05-16 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases

Also Published As

Publication number Publication date
NO20012135L (en) 2001-06-25
JP4205861B2 (en) 2009-01-07
US6913749B2 (en) 2005-07-05
EP1135158A2 (en) 2001-09-26
DE69929240D1 (en) 2006-02-02
NZ511079A (en) 2003-08-29
HK1042844A1 (en) 2002-08-30
EP1135158B1 (en) 2005-12-28
ATE314087T1 (en) 2006-01-15
JP4188353B2 (en) 2008-11-26
ES2255325T3 (en) 2006-06-16
JP2006068015A (en) 2006-03-16
IL142582A0 (en) 2002-03-10
KR20010089364A (en) 2001-10-06
AU771889B2 (en) 2004-04-08
KR100559918B1 (en) 2006-03-13
US20010038843A1 (en) 2001-11-08
CA2348756A1 (en) 2000-05-11
NO20012135D0 (en) 2001-04-30
HUP0105392A2 (en) 2002-04-29
WO2000025722A3 (en) 2000-10-12
WO2000025722A2 (en) 2000-05-11
AU2008100A (en) 2000-05-22
PT1135158E (en) 2006-05-31
HUP0105392A3 (en) 2008-04-28
PL348611A1 (en) 2002-06-03
DK1135158T3 (en) 2006-05-15
JP2002531064A (en) 2002-09-24
DE69929240T2 (en) 2006-08-31
US7459158B2 (en) 2008-12-02
US20030031663A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
JP4188353B2 (en) Enhanced vaccine
RU2711979C2 (en) Interleukin 15 protein complex and use thereof
JP3101690B2 (en) Modifications of or for denatured antibodies
ES2144424T5 (en) VACCINE UNDERSTANDING PART OF THE CONSTANT REGION OF IGE FOR THE TREATMENT OF ALLERGIC REACTIONS INDUCED BY IGE.
US5342924A (en) Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US20030017977A1 (en) Methods of treating inflammatory skin diseases
EP0512064B1 (en) Extracellular segments of human ige immunoglobulin anchoring peptides and antibodies specific therefor
JP2020524000A (en) Anti-BCMA heavy chain only antibody
BR112019026907A2 (en) ANTIBODIES ONLY OF HEAVY CHAIN ANTI-BCMA, POLYNUCLEOTIDE, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, ITS USES AND METHOD TO PRODUCE THE SAME
JPH03501927A (en) Unique antigenic determinants on IgE-producing B lymphocytes
CN108602857A (en) Recombinate IgG Fc polymers
JPH09502708A (en) Recombinant IL4 antibody useful for treating diseases transmitted by IL4
RU2162711C2 (en) Recombinant antibody il4 used for treatment of disorders associated with function of il4
CN110092837A (en) UTI fusion protein
EP0846178A1 (en) Allergen-xcd32 fusion proteins
SAYERS et al. The structural basis of human IgE–Fc receptor interactions
EP1621209A2 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
RU2214279C2 (en) Improved vaccines
AU2672700A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
MXPA01004372A (en) Enhanced vaccines
US20040115220A1 (en) Vaccine
JP2000502995A (en) Compositions and methods for stimulating antibody release by B lymphocytes
EP1123317A1 (en) Immunoglobulin variants
RO116809B1 (en) Recombinant monclonal antibody, pharmaceutical combination and treating method employing the same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION